var title_f23_36_24128="Nasal bridle";
var content_f23_36_24128=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51735&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Nasal bridle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A flexible piece of material is looped around the nasal septum from one nostril to the other as a bridle. The nasoenteric tube is secured to the bridle which prevents movement or dislodgement of the tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery: Scientific Principles and Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24128=[""].join("\n");
var outline_f23_36_24128=null;
var title_f23_36_24129="CT lumbar hernia";
var content_f23_36_24129=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    CT lumbar hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomogram of a left-sided lumbar hernia following nephrectomy for renal cell cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland, MW, Lillemoe, KD. Greenfield's Surgery: Scientific Principles And Practice, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24129=[""].join("\n");
var outline_f23_36_24129=null;
var title_f23_36_24130="Thyroid ultrasound from a patient with Graves disease";
var content_f23_36_24130=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79956&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Thyroid ultrasound from a patient with Graves' disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sonogram of the left thyroid lobe in the longitudinal plane from a patient with Graves' disease. The left panel shows a hypoechoic enlarged lobe (L), while the Doppler image in the right panel shows intense hyperemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manfred Blum, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24130=[""].join("\n");
var outline_f23_36_24130=null;
var title_f23_36_24131="Paragonimiasis adult worm";
var content_f23_36_24131=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77590&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 568px\">",
"   <div class=\"ttl\">",
"    Paragonimiasis adult worm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 548px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Adult of",
"    <em>",
"     P. westermani",
"    </em>",
"    .",
"    <br>",
"     (B) Adult of",
"     <em>",
"      Paragonimus",
"     </em>",
"     spp, taken from a lung biopsy specimen stained with hematoxylin and eosin. Note the presence of the oral sucker. The species was not identified in this case.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Paragonimiasis. Available at:",
"      <a href=\"file://dpd.cdc.gov/dpdx/html/Paragonimiasis.htm\" target=\"_blank\">",
"       file://dpd.cdc.gov/dpdx/html/Paragonimiasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24131=[""].join("\n");
var outline_f23_36_24131=null;
var title_f23_36_24132="Aldridge sterilization";
var content_f23_36_24132=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66609&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Aldridge sterilization",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 542px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24132=[""].join("\n");
var outline_f23_36_24132=null;
var title_f23_36_24133="Tinea cruris 3";
var content_f23_36_24133=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea cruris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24133=[""].join("\n");
var outline_f23_36_24133=null;
var title_f23_36_24134="Triprolidine, pseudoephedrine, and codeine: Drug information";
var content_f23_36_24134=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triprolidine, pseudoephedrine, and codeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/62/18405?source=see_link\">",
"    see \"Triprolidine, pseudoephedrine, and codeine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F231846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CoActifed&reg;;",
"     </li>",
"     <li>",
"      Covan&reg;;",
"     </li>",
"     <li>",
"      ratio-Cotridin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F231856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Alpha-/Beta- Agonist;",
"     </li>",
"     <li>",
"      Analgesic, Opioid;",
"     </li>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      Decongestant;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F231847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Cold, allergy symptoms:",
"     </b>",
"     Oral: 10 mL 4 times/day",
"     <b>",
"      or",
"     </b>",
"     1 tablet 4 times/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F231852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cold, allergy symptoms:",
"     </b>",
"     Oral: Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-6 years: 2.5 mL 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 years: 5 mL 4 times/day",
"     <b>",
"      or",
"     </b>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     tablet 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F231848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5951007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CoActifed&reg;, ratio-Cotridin: Triprolidine hydrochloride 2 mg, pseudoephedrine hydrochloride 30 mg, and codeine phosphate 10 mg per 5 mL (100 mL, 2000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CoVan&reg;: Triprolidine hydrochloride 2 mg, pseudoephedrine hydrochloride 30 mg, and codeine phosphate 10 mg per 5 mL (500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CoActifed&reg;: Triprolidine hydrochloride 4 mg, pseudoephedrine hydrochloride 60 mg, and codeine phosphate 20 mg (50s)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11240924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F231858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CDSA-I",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F231838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of upper respiratory symptoms and cough",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F231864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Triacin-C&reg; may be confused with triacetin",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F231854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, dizziness, drowsiness, dysphoria, euphoria, hallucination, headache, ICP increased, lightheadedness, sedation, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, nausea, vomiting, anorexia, xerostomia, taste disturbance, biliary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary retention, urinary tract spasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle tremor, paresthesia, muscular rigidity (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, nystagmus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Respiratory depression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, physical or psychological dependence with continued use, withdrawal syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F231841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to triprolidine, pseudoephedrine, opiates, or any component of the formulation (some formulations contain ethanol); acute respiratory depression; CNS depression or coma; increased intracranial pressure (ICP)/head trauma; convulsive disorder; acute abdomen/obstruction; use of MAO inhibitors within 14 days",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F231828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Overdosage: Hallucinations, seizures, CNS depression, and death may occur from overdosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenanthrene hypersensitivity: Use with caution in patients with hypersensitivity reactions to other phenanthrene derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease including hypertension, tachycardia, and/or ischemic heart disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with angle-closure glaucoma and/or increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pyloroduodenal obstruction: Use with caution in patients with pyloroduodenal obstruction (including stenotic peptic ulcer).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory diseases including asthma, emphysema, and/or COPD.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use pseudoephedrine with caution in patients &gt;60 years of age; may be more sensitive to adverse effects. Avoid use of triprolidine  (potent anticholinergic agent) due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not recommended as an antitussive for children &lt;2 years of age. May cause paradoxical excitation in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cough control: Codeine is not recommended for use for cough control in patients with a productive cough.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Avoid prolonged use; generally limited to not more than 5 days.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F231853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F231832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Aluminum Hydroxide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Alpha-/Beta-Agonists may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bromocriptine: Alpha-/Beta-Agonists may enhance the adverse/toxic effect of Bromocriptine. Including increased blood pressure, ventricular arrhythmias, and seizure.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May decrease the excretion of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha-/Beta-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: Alpha-/Beta-Agonists (Indirect-Acting) may decrease the serum concentration of FentaNYL. Specifically, fentanyl nasal spray serum concentrations may decrease and onset of effect may be delayed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May enhance the tachycardic effect of Alpha-/Beta-Agonists. Serotonin/Norepinephrine Reuptake Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spironolactone: May diminish the vasoconstricting effect of Alpha-/Beta-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F231844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14457256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14457258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14457257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F231842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actifed Antitusivo (PE);",
"     </li>",
"     <li>",
"      Actifed Compound (TH);",
"     </li>",
"     <li>",
"      Actifed Compound Linctus (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, HK, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      CoActifed (CA);",
"     </li>",
"     <li>",
"      Covan (CA);",
"     </li>",
"     <li>",
"      Fedac Compound (HK, MY);",
"     </li>",
"     <li>",
"      ratio-Cotridin (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F231840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See Pseudoephedrine and Codeine monographs.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24134/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10103 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-7B7E1375F2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24134=[""].join("\n");
var outline_f23_36_24134=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854543\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231846\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231856\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231847\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231852\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231848\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951007\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11240924\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231858\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231838\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231864\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231854\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231841\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231828\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231853\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231832\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231844\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14457256\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14457258\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14457257\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231842\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F231840\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10103|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/62/18405?source=related_link\">",
"      Triprolidine, pseudoephedrine, and codeine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_36_24135="Management of pregnant women after inhibition of acute preterm labor";
var content_f23_36_24135=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of pregnant women after inhibition of acute preterm labor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Steve Caritis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Hyagriv N Simhan, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24135/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/36/24135/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of pregnancies after resolution of an acute episode of preterm labor (PTL) is unknown. No large randomized trials have compared various management strategies.",
"   </p>",
"   <p>",
"    This topic will review management of women after treatment of idiopathic PTL and without advanced cervical dilation. The acute evaluation and management of women with suspected PTL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=see_link\">",
"     \"Overview of preterm labor and birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24606130\">",
"    <span class=\"h2\">",
"     Is hospitalization useful?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that prolonged hospitalization is useful in stable patients after evaluation and management of an episode of suspected PTL have been completed. Advanced cervical dilatation, vaginal bleeding, nonreassuring fetal status, or a long travel time to a hospital with appropriate levels of obstetric and neonatal care services are some examples of an unstable situation. Each of these situations is associated with an increased probability of birth away from a tertiary care center and a birth that incurs significant morbidity to mother",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    newborn. Therefore, in these situations, ongoing in-hospital observation may be useful.",
"   </p>",
"   <p>",
"    The only randomized trial designed to determine whether hospitalization of women with arrested PTL increased the proportion of deliveries &ge;36 weeks compared to women discharged home did not find a benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/1\">",
"     1",
"    </a>",
"    ]. In this trial, 101 women with singleton gestations, intact membranes, mean cervical dilation of 2.7 cm, and a diagnosis of arrested PTL between",
"    <span class=\"nowrap\">",
"     24",
"     <sup>",
"      0/7",
"     </sup>",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     33",
"     <sup>",
"      4/7",
"     </sup>",
"    </span>",
"    weeks of gestation were randomly assigned to hospitalization until 34 weeks of gestation or discharged home upon completion of a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . Tocolytics were not used; contractions ceased with conservative management alone. In both groups, about 70 percent of women delivered &ge;36. This trial was underpowered and is not generalizable to the more clinically relevant population of women with arrested PTL after tocolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24606278\">",
"    <span class=\"h2\">",
"     Is bed rest indicated?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence that bed rest is effective for prevention of spontaneous preterm birth in singletons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/3,4\">",
"     3,4",
"    </a>",
"    ] or twins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/5\">",
"     5",
"    </a>",
"    ]. Bed rest has potential harms: it promotes loss of trabecular bone density, increases venous thromboembolism risk, produces musculoskeletal deconditioning, and places significant psychosocial strain on individuals and families [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/3,6-12\">",
"     3,6-12",
"    </a>",
"    ]. Based on lack of evidence of efficacy in prematurity prevention, and known significant risks, we suggest not prescribing bed rest for women with a recent history of PTL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24606285\">",
"    <span class=\"h2\">",
"     Should exercise and work be avoided?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most trials of exercise in pregnancy have excluded women at risk for PTL or who develop PTL during the trial; therefore, it is difficult to assess the effect of exercise on these women. A systematic review found that healthy women who engaged in aerobic exercise had no clinically important shortening of gestation compared to those who reduced their level of exercise or did not exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/13\">",
"     13",
"    </a>",
"    ]. By comparison, another systematic review concluded that physically-demanding work may be modestly associated with preterm birth (OR 1.22, 95% CI 1.16-1. 29) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/14\">",
"     14",
"    </a>",
"    ]. Many occupational activities are complex constructs involving duration of work, shift effects, psychological and physical stress, lifting (frequency and amount of weight), length of time standing, etc, and thus cannot readily be characterized in a simple way. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20056?source=see_link&amp;anchor=H6#H6\">",
"     \"Work and pregnancy\", section on 'Demands of workplace and perinatal outcome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H19#H19\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Physical activity and work'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of similar studies in women at increased risk for preterm birth, we feel it is reasonable to suggest modification of activities for women who have had one or more episodes of PTL. In particular, we suggest that patients avoid working more than 40 hours per week, night work, prolonged standing (more than a total of eight hours or more than four continuous hours per 24-hour period), and heavy physical work, as this activity level has been variably associated with PTL and preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/14-17\">",
"     14-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24606332\">",
"    <span class=\"h2\">",
"     Should sexual activity be avoided?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no strong evidence that sexual activity affects the risk of preterm birth or onset of labor in healthy women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=see_link&amp;anchor=H20#H20\">",
"     \"Risk factors for preterm labor and delivery\", section on 'Coitus'",
"    </a>",
"    .) Both prostaglandins in semen and orgasm can contribute to increases in myometrial activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. For this reason, it is appropriate to discuss with patients that contractions may occur with greater frequency and intensity after intercourse, and it is reasonable to suggest avoidance of intercourse for women with an arrested episode of preterm labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34955464\">",
"    <span class=\"h2\">",
"     Should travel be avoided?",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is unlikely that travel will cause PTL or preterm birth, women who wish to travel need to consider the risk of pregnancy complications away from their usual source of medical care, as well as the availability of medical resources and their medical insurance coverage at their destination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9738349\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal fibronectin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data supporting the use of fetal fibronectin (fFN) testing to further stratify risk status of fFN positive women after an episode of acute PTL. We do not recommend fFN testing to monitor asymptomatic women who are clinically stable after an episode of acute PTL, whether or not they have had a previous fFN test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=see_link\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Home uterine activity monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from randomized trials of home uterine monitoring have reported inconsistent results and many have had serious design flaws. A meta-analysis of well-designed trials found that home uterine activity monitoring did not significantly decrease the frequency of preterm delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/20\">",
"     20",
"    </a>",
"    ]. Based on these data, the American College of Obstetricians and Gynecologists and other expert organizations do not recommend the use of home uterine activity monitoring to monitor women at risk for PTL or recurrent PTL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9738527\">",
"    <span class=\"h1\">",
"     MEDICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Maintenance tocolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several theoretical rationales for considering maintenance tocolysis after successful arrest of the initial episode of PTL: (1) the underlying stimulus for labor may persist and cause a recurrence; (2) the myometrium, having experienced a recent episode of PTL, may be in a chemical state of preparedness and thus have a low threshold for recurrence; and (3) contractions may have positive feedback on myometrial contractility and lead to further contractions. For example, elevated endogenous prostaglandins are known to increase oxytocin receptor density [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/23\">",
"     23",
"    </a>",
"    ]. The inhibition of contractions, therefore, may reduce prostaglandin production and oxytocin receptor up-regulation.",
"   </p>",
"   <p>",
"    The bulk of evidence, however, does",
"    <strong>",
"     not",
"    </strong>",
"    support the use of maintenance tocolytic therapy after an acute episode of PTL for prevention of preterm birth. There have been over a dozen randomized trials in which maintenance tocolysis was compared to placebo or to no treatment after arrest of acute PTL in patients with intact membranes (",
"    <a class=\"graphic graphic_table graphicRef75878 \" href=\"UTD.htm?12/14/12525\">",
"     table 1",
"    </a>",
"    ). Most trials have been small and with study design limitations. The range of findings is illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      &mdash; In two randomized trials comparing nifedipine to placebo, women treated with nifedipine maintained pregnancy one to four days longer than women who received no therapy, but this difference was not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. The trials were too small (74 and 68 participants) to detect anything but large differences (&gt;35 percent) in efficacy. Another small trial (n = 73 participants) reported significantly longer prolongation of pregnancy (27 versus 16 days) and gestational age at delivery (37 versus 35 weeks) in the nifedipine group [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/26\">",
"       26",
"      </a>",
"      ]. However, in the largest trial (n = 406 participants), women in the nifedipine group had similar perinatal outcomes, prolongation of pregnancy, and gestational age at delivery as those in the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Beta-agonists",
"      </strong>",
"      &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Nine randomized trials evaluated beta-agonist therapy: one of the nine reported beta-agonist therapy was superior to placebo for prolonging pregnancy and two reported this therapy reduced the risk of recurrent PTL. The sample sizes in these three trials were small, but the effect size was large, thus allowing for a statistical difference to be demonstrated.",
"      <br/>",
"      <br/>",
"      On the other hand, four of the nine trials reported beta-agonist therapy was no better than placebo in prolonging pregnancy or preventing recurrent PTL. These four trials, however, are of limited value because the prevalence of preterm birth was low; therefore, a very large sample size would be needed to demonstrate whether drug therapy was superior to placebo. The trials were too small to exclude the possibility of clinically-important differences in outcome.",
"      <br/>",
"      <br/>",
"      The remaining trial also found no benefit of beta-agonist maintenance therapy over placebo in prolonging pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/28\">",
"       28",
"      </a>",
"      ]. Although the authors found a possible benefit in the subgroup of patients with PTL prior to 32 weeks of gestation, this analysis was performed post hoc and needs to be confirmed in a prospective, randomized trial. The observed benefit may be because women with contractions recruited after 32 weeks of gestation are having normal uncoordinated uterine contractions and cervical ripening and thus are often not at great risk of preterm delivery; their inclusion in tocolysis trials limits the ability of the trial to determine treatment efficacy.",
"     </li>",
"     <li>",
"      A Cochrane review, which included 11 randomized trials comparing oral beta-mimetics with alternative therapies or placebo for maintenance therapy after threatened PTL, concluded there was no significant benefit to oral beta-mimetic therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/29\">",
"       29",
"      </a>",
"      ]. Outcomes evaluated included rate of NICU admission, preterm birth, perinatal mortality, and perinatal morbidity.",
"     </li>",
"     <li>",
"      The US Food and Drug Administration concluded that the risk of serious adverse events from prolonged",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      therapy of preterm labor (beyond 48 to 72 hours) outweighs any potential benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The Agency for Healthcare Research and Quality reviewed available data and found that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      pump therapy could be beneficial for maintenance tocolysis, but most studies were biased so there was low confidence in this conclusion; in addition, the safety of this therapy was unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      &mdash; Oral magnesium is not well absorbed and causes diarrhea. Moreover, a Cochrane review concluded that oral magnesium sulfate did not appear to be effective for preventing preterm birth after threatened PTL, although data were limited [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/32\">",
"       32",
"      </a>",
"      ]. Magnesium sulfate did not reduce preterm birth compared to placebo or alternative therapy.",
"     </li>",
"     <li>",
"      <strong>",
"       Atosiban",
"      </strong>",
"      &mdash; The only randomized trial comparing an oxytocin antagonist (atosiban) to placebo for maintenance therapy after an episode of PTL did not find that active therapy significantly reduced preterm birth before 28, 32, or 37 weeks of gestation, but prolonged the time to first recurrence of labor (32.6 days with atosiban versus 27.6 days with placebo) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/33\">",
"       33",
"      </a>",
"      ]. This double-blind multicenter trial included 513 patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, there is no high-quality evidence of benefit from maintenance tocolysis in terms of prolongation of pregnancy and prevention of preterm birth. Maintenance tocolysis may have a role in providing symptomatic relief with respect to intensity and frequency of contractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Progesterone supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are already receiving supplemental progesterone for prevention of preterm birth because of a history of prior preterm birth or because of the finding of a sonographic short cervix should continue to receive the supplemental progesterone after an episode of PTL. Progesterone supplementation after arrested PTL appears to prolong latency compared to no supplementation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized trial of 60 women who remained undelivered after an episode of preterm labor reported treatment with 17-alpha-hydroxyprogesterone caproate (341 mg twice weekly) was associated with less shortening of the cervix and a reduced rate of preterm delivery compared with observation alone [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A similar trial randomly assigned 70 women who remained undelivered after an episode of preterm labor to progesterone vaginal suppository (400 mg daily) or no intervention [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/35\">",
"       35",
"      </a>",
"      ]. Progesterone maintenance therapy was associated with longer latency, fewer preterm births and complications of prematurity, and higher birth weight than expectant management, although some of the results did not reach statistical significance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of spontaneous preterm birth\", section on 'Supplemental progesterone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of another indication for progesterone supplementation (eg, prior spontaneous preterm birth, sonographic short cervix), we recommend not using progesterone as an adjunct to tocolysis nor as part of maintenance therapy after an arrested episode of PTL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Repeated courses of antenatal corticosteroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A course of antenatal corticosteroids is given to women at risk for preterm birth to reduce neonatal morbidity and mortality if preterm delivery occurs; these drugs do not prevent PTL or preterm birth. We do not recommend routine weekly courses of antenatal corticosteroid therapy. The indications for",
"    <span class=\"nowrap\">",
"     rescue/salvage/booster",
"    </span>",
"    therapy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H667637#H667637\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Use of repeated courses of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotic prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven benefit to use of prophylactic broad-spectrum antibiotics to delay delivery in the setting of PTL with intact membranes. A systematic review and meta-analysis of trials of asymptomatic nonlaboring women at high risk of preterm birth randomly assigned to prophylactic antibiotic therapy or placebo found therapy did not significantly reduce the risk of subsequent preterm birth, irrespective of criteria used to assess risk, the antimicrobial agent administered, or gestational age at time of treatment (relative risk of delivery at less than 37 weeks with antibiotic treatment 1.03; 95% CI 0.86-1.24; 17 trials, 9584 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/36\">",
"     36",
"    </a>",
"    ]. A subsequent meta-analysis of trials of routine antibiotic prophylaxis in pregnancy affirmed these findings (RR 1.02, 95% CI 0.86-1.22; 8 trials, over 6200 women) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9739002\">",
"    <span class=\"h3\">",
"     GBS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Likewise, there is no benefit to GBS chemoprophylaxis (even if GBS rectovaginal culture is positive) once the patient is no longer at imminent risk of preterm birth (",
"    <a class=\"graphic graphic_algorithm graphicRef72587 \" href=\"UTD.htm?36/22/37230\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24135/abstract/38\">",
"     38",
"    </a>",
"    ]. Guidelines for GBS prophylaxis are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=see_link&amp;anchor=H14#H14\">",
"     \"Chemoprophylaxis for the prevention of neonatal group B streptococcal disease\", section on 'Approach to threatened preterm delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Follow-up visits for both singleton and twin pregnancies are usually scheduled on a weekly basis to review signs and symptoms of PTL and to evaluate whether there has been further cervical change. Typically, this evaluation is performed by digital examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sterile speculum inspection of the cervix. This examination permits the detection of further cervical dilation or effacement in the setting of minimal to no symptoms. As an example, a woman whose cervix was noted to be 2 cm of dilation on hospital discharge who subsequently is noted to have a cervical exam consistent with 4 cm of dilation may warrant hospitalized observation in case of precipitous delivery.",
"   </p>",
"   <p>",
"    After acute labor inhibition, we do not routinely recommend a specific strategy of antenatal fetal assessment (nonstress tests, biophysical profile) or serial ultrasound examinations for fetal growth assessment unless there is a medical or obstetrical indication. Preterm labor alone is not an indication for antenatal fetal surveillance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=see_link\">",
"     \"Overview of fetal assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific patient instructions upon hospital discharge are individualized based on factors such as her distance from the hospital, the nature of her symptoms, her gestational age, and her past and current obstetrical history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=see_link\">",
"       \"Patient information: Preterm labor (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no large, well-designed randomized trials on which to base management of women after an episode of preterm labor.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest outpatient management for stable patients (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Advanced cervical dilatation, vaginal bleeding, nonreassuring fetal status, or a long travel time to a hospital with appropriate levels of obstetric and neonatal care services are signs of an unstable situation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Physical activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest patients avoid demanding physical activity and sexual intercourse (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24606285\">",
"       'Should exercise and work be avoided?'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24606332\">",
"       'Should sexual activity be avoided?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fetal fibronectin testing and home uterine activity monitoring are not useful for monitoring women with an episode of arrested preterm labor. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fetal fibronectin testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Home uterine activity monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not using maintenance tocolysis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Maintenance tocolysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not using prophylactic antibiotics for prevention of recurrent preterm labor (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antibiotic prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend not routinely repeating courses of antenatal corticosteroid therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <span class=\"nowrap\">",
"       Rescue/salvage/booster",
"      </span>",
"      therapy is indicated in select women and discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=see_link&amp;anchor=H667637#H667637\">",
"       \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\", section on 'Use of repeated courses of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supplemental progesterone may be useful for prolonging latency; however, additional data confirming this benefit are needed before we can make a clinical recommendation for or against its routine use. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Progesterone supplementation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/1\">",
"      Yost NP, Bloom SL, McIntire DD, Leveno KJ. Hospitalization for women with arrested preterm labor: a randomized trial. Obstet Gynecol 2005; 106:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/2\">",
"      Goldenberg RL. Arrested preterm labor: do the data support home or hospital care? Obstet Gynecol 2005; 106:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/3\">",
"      Goldenberg RL, Cliver SP, Bronstein J, et al. Bed rest in pregnancy. Obstet Gynecol 1994; 84:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/4\">",
"      Sosa C, Althabe F, Beliz&aacute;n J, Bergel E. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2004; :CD003581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/5\">",
"      Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; :CD000110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/6\">",
"      Allen C, Glasziou P, Del Mar C. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet 1999; 354:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/7\">",
"      Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. Am J Obstet Gynecol 2000; 182:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/8\">",
"      Maloni JA, Schneider BS. Inactivity: symptoms associated with gastrocnemius muscle disuse during pregnancy. AACN Clin Issues 2002; 13:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/9\">",
"      Maloni JA, Kane JH, Suen LJ, Wang KK. Dysphoria among high-risk pregnant hospitalized women on bed rest: a longitudinal study. Nurs Res 2002; 51:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/10\">",
"      Maloni JA, Alexander GR, Schluchter MD, et al. Antepartum bed rest: maternal weight change and infant birth weight. Biol Res Nurs 2004; 5:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/11\">",
"      Maloni JA, Park S. Postpartum symptoms after antepartum bed rest. J Obstet Gynecol Neonatal Nurs 2005; 34:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/12\">",
"      Promislow JH, Hertz-Picciotto I, Schramm M, et al. Bed rest and other determinants of bone loss during pregnancy. Am J Obstet Gynecol 2004; 191:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/13\">",
"      Kramer MS. Aerobic exercise for women during pregnancy. Cochrane Database Syst Rev 2002; :CD000180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/14\">",
"      Mozurkewich EL, Luke B, Avni M, Wolf FM. Working conditions and adverse pregnancy outcome: a meta-analysis. Obstet Gynecol 2000; 95:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/15\">",
"      McCulloch J. Health risks associated with prolonged standing. Work 2002; 19:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/16\">",
"      Luke B, Mamelle N, Keith L, et al. The association between occupational factors and preterm birth: a United States nurses' study. Research Committee of the Association of Women's Health, Obstetric, and Neonatal Nurses. Am J Obstet Gynecol 1995; 173:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/17\">",
"      Bonzini M, Coggon D, Palmer KT. Risk of prematurity, low birthweight and pre-eclampsia in relation to working hours and physical activities: a systematic review. Occup Environ Med 2007; 64:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/18\">",
"      Goodlin RC, Schmidt W, Creevy DC. Uterine tension and fetal heart rate during maternal orgasm. Obstet Gynecol 1972; 39:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/19\">",
"      Sahmay S, Atasu T, Karacan I. The effect of intrauterine insemination on uterine activity. Int J Fertil 1990; 35:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/20\">",
"      Urquhart C, Currell R, Harlow F, Callow L. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev 2012; 5:CD006172.",
"     </a>",
"    </li>",
"    <li>",
"     Agency for Healthcare Research and Quality. Management of preterm labor. Evidence report /Technology Assessment #18. Rockville, Maryland. 2000.",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Management of preterm labor. ACOG practice bulletin 43. May 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/23\">",
"      Soloff MS, Jeng YJ, Copland JA, et al. Signal pathways mediating oxytocin stimulation of prostaglandin synthesis in select target cells. Exp Physiol 2000; 85 Spec No:51S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/24\">",
"      Carr DB, Clark AL, Kernek K, Spinnato JA. Maintenance oral nifedipine for preterm labor: a randomized clinical trial. Am J Obstet Gynecol 1999; 181:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/25\">",
"      Lyell DJ, Pullen KM, Mannan J, et al. Maintenance nifedipine tocolysis compared with placebo: a randomized controlled trial. Obstet Gynecol 2008; 112:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/26\">",
"      Sayin NC, Varol FG, Balkanli-Kaplan P, Sayin M. Oral nifedipine maintenance therapy after acute intravenous tocolysis in preterm labor. J Perinat Med 2004; 32:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/27\">",
"      Roos C, Spaanderman ME, Schuit E, et al. Effect of maintenance tocolysis with nifedipine in threatened preterm labor on perinatal outcomes: a randomized controlled trial. JAMA 2013; 309:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/28\">",
"      Lewis R, Mercer BM, Salama M, et al. Oral terbutaline after parenteral tocolysis: a randomized, double-blind, placebo-controlled trial. Am J Obstet Gynecol 1996; 175:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/29\">",
"      Dodd JM, Crowther CA, Dare MR, Middleton P. Oral betamimetics for maintenance therapy after threatened preterm labour. Cochrane Database Syst Rev 2006; :CD003927.",
"     </a>",
"    </li>",
"    <li>",
"     Terbutaline: Label Change - Warnings Against Use for Treatment of Preterm Labor file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm243843.htm (Accessed on February 17, 2011).",
"    </li>",
"    <li>",
"     Gaudet L, Singh K, Weeks L, Skidmore B, Tsouros S, Tsertsvadze A,",
"Daniel R, Doucette S, Walker M, Ansari MT. Terbutaline Pump for the Prevention of Preterm",
"Birth. Comparative Effectiveness Review No. 35. (Prepared by the University of Ottawa",
"Evidence-based Practice Center under Contract No. HHSA290-2007-10059-I.) AHRQ",
"Publication No. 11-EHC068-EF. Rockville, MD: Agency for Healthcare Research and Quality.",
"September 2011. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/32\">",
"      Crowther CA, Moore V. Magnesium for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2000; :CD000940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/33\">",
"      Valenzuela GJ, Sanchez-Ramos L, Romero R, et al. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group. Am J Obstet Gynecol 2000; 182:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/34\">",
"      Facchinetti F, Paganelli S, Comitini G, et al. Cervical length changes during preterm cervical ripening: effects of 17-alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 2007; 196:453.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/35\">",
"      Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2008; 48:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/36\">",
"      Simcox R, Sin WT, Seed PT, et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. Aust N Z J Obstet Gynaecol 2007; 47:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/37\">",
"      van den Broek NR, White SA, Goodall M, et al. The APPLe study: a randomized, community-based, placebo-controlled trial of azithromycin for the prevention of preterm birth, with meta-analysis. PLoS Med 2009; 6:e1000191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24135/abstract/38\">",
"      Verani JR, McGee L, Schrag SJ, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6795 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24135=[""].join("\n");
var outline_f23_36_24135=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSICAL ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24606130\">",
"      Is hospitalization useful?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24606278\">",
"      Is bed rest indicated?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24606285\">",
"      Should exercise and work be avoided?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24606332\">",
"      Should sexual activity be avoided?",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34955464\">",
"      Should travel be avoided?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9738349\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal fibronectin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Home uterine activity monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9738527\">",
"      MEDICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Maintenance tocolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Progesterone supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Repeated courses of antenatal corticosteroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotic prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9739002\">",
"      - GBS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6795|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?36/22/37230\" title=\"algorithm 1\">",
"      CDC algorithm for screening for GBS in preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6795|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/14/12525\" title=\"table 1\">",
"      Maintenance tocolysis trials",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/57/19354?source=related_link\">",
"      Chemoprophylaxis for the prevention of neonatal group B streptococcal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30121?source=related_link\">",
"      Overview of fetal assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5608?source=related_link\">",
"      Overview of preterm labor and birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/52/35650?source=related_link\">",
"      Patient information: Preterm labor (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/45/11994?source=related_link\">",
"      Prevention of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20056?source=related_link\">",
"      Work and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_36_24136="Antithrombin (ATIII) deficiency";
var content_f23_36_24136=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antithrombin (ATIII) deficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24136/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24136/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24136/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24136/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24136/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24136/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/36/24136/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited thrombophilia is a genetic tendency to venous thromboembolism. The Factor V Leiden and prothrombin gene mutations are the most common causes of the syndrome accounting for more than 50 percent of cases in Caucasians. Deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include the dysfibrinogenemias [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The total incidence of an inherited thrombophilia in subjects with a deep vein thrombosis ranges from 24 to 37 percent overall compared with about 10 percent in controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the genetics, prevalence, clinical presentation and diagnosis of antithrombin deficiency. Issues related to screening for and the general treatment of the inherited thrombophilias are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=see_link\">",
"     \"Evaluation of the patient with established venous thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=see_link\">",
"     \"Screening for inherited thrombophilia in asymptomatic populations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link\">",
"     \"Management of inherited thrombophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF ANTITHROMBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin (AT, formerly called AT III, also known as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor I), a natural anticoagulant, is a vitamin K-independent glycoprotein that is a major inhibitor of thrombin and other coagulation serine proteases (ie, a serpin), including factors Xa and IXa [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/3\">",
"     3",
"    </a>",
"    ]. Augmentation of its inhibitory activity by heparin constitutes the basis for the clinical use of heparin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antithrombin exists in two forms in the plasma, an active monomer and an inactive \"latent\" form [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/4\">",
"     4",
"    </a>",
"    ]. One molecule of latent antithrombin can inactivate one molecule of the active monomer through the formation of a heterodimer; in health, this process only contributes to the normal turnover of the protein in plasma. However, this process can be accelerated at physiologic pH and temperature, and may explain onset of thrombosis in carriers of rare unstable variants of antithrombin during fever and ill health.",
"   </p>",
"   <p>",
"    AT slowly inactivates thrombin in the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    which is called progressive antithrombin activity. In the presence of heparin, thrombin or factor Xa is rapidly inactivated by AT; this is referred to as the heparin cofactor activity of AT.",
"   </p>",
"   <p>",
"    AT has two active functional sites: the reactive center, Arg393-Ser394; and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding site located near the amino terminus of the molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Thrombin cleaves the reactive site followed by the formation of an inactive complex which is rapidly cleared from the circulation. The binding of heparin to the heparin binding site on AT produces a conformational change in AT which accelerates the inactivating process by 4000-fold.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     GENETICS OF ANTITHROMBIN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin is an alpha-2-globulin composed of 432 amino acids. It is synthesized in the liver as a 464 amino acid precursor from which a 32 amino acid signal peptide is cleaved. The signal peptide plays a crucial role in translocation of the protein into the endoplasmic reticulum where cotranslational processing takes place [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/7\">",
"     7",
"    </a>",
"    ]. The gene for AT has been localized to the long arm of chromosome 1 and contains seven exons and six introns [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hereditary AT deficiency was the first identified cause of hereditary thrombophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. It is usually inherited in an autosomal dominant fashion, with variable clinical penetrance, affecting both sexes equally. More than 127 different mutations of AT have been identified, which mostly occur in the heterozygous state [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/13\">",
"     13",
"    </a>",
"    ]. Homozygous type I AT deficiency (see below) has not been described in humans, suggesting that it is incompatible with life. Homozygous knockout of the antithrombin gene is lethal in mice, consistent with this observation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two major types of inherited AT deficiency have been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type I",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type I deficiency state results from reduced synthesis of biologically normal protease inhibitor molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/15\">",
"     15",
"    </a>",
"    ]. In these cases, the antigenic and functional activity of AT in the blood are reduced in parallel. The values are reduced by approximately 50 percent in the heterozygote.",
"   </p>",
"   <p>",
"    The molecular basis for this disorder is either a deletion of a major segment of the AT gene or, more commonly, small",
"    <span class=\"nowrap\">",
"     deletions/insertions",
"    </span>",
"    (less than 22 base pairs) or single base substitutions. Most mutations interfere with synthesis of the protein. One mutation has been reported that impairs cotranslational processing due to an amino acid substitution in the hydrophobic domain of the AT signal peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Type II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type II AT deficiency is produced by a discrete molecular defect within the protein. Plasma AT functional activity is markedly reduced, whereas AT immunologic activity is essentially normal.",
"   </p>",
"   <p>",
"    Using only an immunoassay for measuring plasma levels of AT levels, initial estimates of the prevalence of AT deficiency in the general population were one in 2000 to 5000 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/16\">",
"     16",
"    </a>",
"    ]. However, studies employing functional assays that measure AT-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor activity have found that the prevalence of AT deficiency in the general population may be as high as one in 500 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The majority of AT-deficient patients identified in these studies did not have a personal or familial history of thrombosis and had a type II defect with mutations at the heparin binding site (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with a first thrombotic event, the prevalence of hereditary AT deficiency is approximately 0.5 to 1 percent, being less common than factor V Leiden, the prothrombin gene mutation, or protein S or protein C deficiency (see",
"    <a class=\"local\" href=\"#H11\">",
"     'Risk of deep vein thrombosis'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/1,20\">",
"     1,20",
"    </a>",
"    ]. On very rare occasions, AT deficiency comes to clinical attention when homozygous children of consanguineous parents who were asymptomatic carriers develop severe venous or arterial thrombosis in association with plasma AT-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor levels below 10 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AT-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor and progressive AT activity assays (see below) have identified AT-deficient patients with reductions in heparin cofactor activity with or without concordant decrements in progressive AT activity. Three subtypes of the type II phenotype have been described. The relative prevalence of the three types depends upon how the patients are selected. Among thrombophilic families, type I defects are probably more prevalent than type II thrombin-binding site defects. If one screens the general population, type II heparin-binding site defects are most prevalent and the relative frequencies are approximately one in 500.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Heparin binding site defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several abnormal AT molecules have been identified with defects at a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding site, resulting in isolated reductions in heparin cofactor activity. These variants generally have mutations at the amino-terminal end of the molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/20\">",
"     20",
"    </a>",
"    ]. Affected individuals generally have plasma AT-heparin cofactor activity measurements of approximately 50 percent and normal progressive AT activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Thrombin binding site defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Variants with decreased activity in both AT functional assays generally have mutations near the thrombin binding site at the carboxyterminal end of the molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Pleiotropic defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The third subtype involves a mutation at the carboxyterminal end of the AT molecule between amino acids 402-429. These mutations produce conformational changes in the protein and can exhibit multiple defects including reductions in both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding and progressive antithrombin activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/24-31\">",
"     24-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mutation in the first reported AT variant, Budapest [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/28\">",
"       28",
"      </a>",
"      ], consisted of replacement of a proline by leucine at residue 429, leading to a molecular defect that affects both the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and thrombin binding sites [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subjects in two other pedigrees (in Utah and Oslo) appear to have a type I deficiency state as determined by routine laboratory testing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/26,27,30,31\">",
"       26,27,30,31",
"      </a>",
"      ]. The similar characteristics of these mutations suggest that the region of residues 402 to 407 is important for the maintenance of normal plasma levels of AT antigen [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/27\">",
"       27",
"      </a>",
"      ]. The mutant AT molecules synthesized by the liver of these deficient individuals seem to be unstable and may be susceptible to increased intracellular degradation, decreased extracellular export, or enhanced clearance upon entry into the circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe thrombotic disease is characteristic of type I AT deficiency and of type II patients with defects affecting the thrombin binding domain. Approximately 55 percent of such patients experience venous thrombotic episodes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/25,32\">",
"     25,32",
"    </a>",
"    ]. Thrombotic events are much less common in heterozygous patients with defects in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    binding domain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/20,33,34\">",
"     20,33,34",
"    </a>",
"    ], occurring in only 6 percent of cases in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/33\">",
"     33",
"    </a>",
"    ]. In contrast, individuals who are homozygous for abnormalities in the heparin binding domain can have severe thrombotic disease.",
"   </p>",
"   <p>",
"    The initial thrombotic event occurs spontaneously in about 42 percent of subjects, while the remaining cases occur in association with pregnancy, oral contraceptives, surgery, or trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/35\">",
"     35",
"    </a>",
"    ]. The most common sites of disease are the deep veins of the leg and the iliofemoral veins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/25,32,35\">",
"     25,32,35",
"    </a>",
"    ] and the mesenteric veins [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Less frequently involved sites include the vena cava and the renal, retinal, cerebral, or hepatic veins (Budd-Chiari syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Arterial thrombosis has been reported but is not characteristic of AT deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 60 percent of individuals develop recurrent thrombotic episodes, and clinical signs of pulmonary embolism are evident in 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/35\">",
"     35",
"    </a>",
"    ]. Thrombotic episodes are rare before puberty; they start to occur with some frequency after puberty, with the risk increasing substantially with advancing age and a peak between 15 and 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heparin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some people with AT deficiency demonstrate resistance to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H12#H12\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Heparin resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Risk of deep vein thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thrombotic risk associated with AT deficiency and other inherited thrombophilias has been assessed in two ways: evaluation of patients with deep vein thrombosis and evaluation of families with thrombophilia. In a Spanish study of 2132 consecutive unselected patients with venous thromboembolism, for example, 12.9 percent had an anticoagulant protein deficiency (7.3 percent with protein S, 3.2 percent with protein C, and 0.5 percent with antithrombin) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/1\">",
"     1",
"    </a>",
"    ]. Similar findings were noted in a series of 277 Dutch outpatients with deep vein thrombosis: 8.3 percent had an isolated deficiency of antithrombin, protein C, protein S, or plasminogen compared with 2.2 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The absolute risk of thrombosis among patients with inherited thrombophilia was evaluated in a report of 150 pedigrees which compared the risk for thrombosis in individuals with inherited thrombophilia due to factor V Leiden or to antithrombin, protein C, or protein S deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/44\">",
"     44",
"    </a>",
"    ]. The lifetime probability of developing thrombosis compared with those with no defect was 8.5 times higher for carriers of protein S deficiency, 8.1 for antithrombin deficiency, 7.3 for protein C deficiency, and 2.2 for factor V Leiden. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Inherited thrombophilia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with AT deficiency appear to be at particularly high risk during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/45\">",
"     45",
"    </a>",
"    ]. One study, for example, evaluated 78 women with inherited deficiency in AT, protein S, or protein C [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/46\">",
"     46",
"    </a>",
"    ]. Deep vein thrombosis occurred in 18 percent of patients with type I AT deficiency during pregnancy and in 33 percent in the postpartum period. By comparison, thrombosis during pregnancy occurred in only 7 percent of patients with protein C deficiency and in none of the patients with protein S deficiency. Thrombosis in the postpartum period occurred in 19 percent of protein C and 17 percent of protein S deficient patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ASSAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunoassays provide quantification of AT antigen and can be used to diagnose type I AT deficiency. Type II deficiencies can only be diagnosed with functional assays of AT activity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The progressive AT activity assay quantifies the capacity of AT to neutralize the enzymatic activity of thrombin in the absence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . It is sensitive to functional deficiency produced by defects in the thrombin binding site but not the heparin binding site. This assay is no longer used clinically.",
"     </li>",
"     <li>",
"      The AT-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      cofactor assay measures the ability of heparin to bind to lysyl residues on AT and catalyze the neutralization of coagulation enzymes such as thrombin and factor Xa. The test can be either a thrombin inhibition assay or a factor Xa inhibition assay depending upon the enzyme that is used.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The factor Xa inhibition assay is preferred for the following reason.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    cofactor II (AT is heparin cofactor I) is another protein in human plasma that exhibits heparin cofactor activity [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. In contrast to AT, heparin cofactor II does not inhibit factor Xa or other serine proteases and requires concentrations of heparin of at least 1",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    in the reaction mixture to function as an efficient inhibitor of thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/48\">",
"     48",
"    </a>",
"    ]. Many functional AT assays employ heparin concentrations greater than 1",
"    <span class=\"nowrap\">",
"     unit/mL;",
"    </span>",
"    as a result, an assay based on factor Xa inhibition is likely to be more specific than one based on thrombin inhibition to identify patients with congenital AT deficiency. In one study of 67 members of a family with type 2 deficiency, for example, six had borderline AT levels with the thrombin inhibition assay, compared with none with the factor Xa inhibition assay [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AT-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor assay will detect all currently recognized subtypes of familial AT deficiency and is therefore the best single laboratory screening test for this disorder. An immunoassay in combination with the AT-heparin cofactor assay will then permit distinction between type I (reduced synthesis) and type II (reduced function) deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/3,51\">",
"     3,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Timing of screening and effect of anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important consideration in the laboratory evaluation of patients with a suspected deficiency of antithrombin, protein C, or protein S is the timing of testing. Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, or anticoagulant therapy on the concentrations of these plasma proteins (see below).",
"   </p>",
"   <p>",
"    The AT-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor assay should be performed when the patient is off heparin, as heparin can lower AT levels by approximately 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/52\">",
"     52",
"    </a>",
"    ]. It has been reported that oral anticoagulants rarely raise plasma AT concentrations into the normal range in individuals with hereditary AT deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/10\">",
"     10",
"    </a>",
"    ]. To exclude this possibility, it is optimal to test for AT deficiency at least two weeks after completing the initial three- to six-month course of oral anticoagulant therapy following a thrombotic event.",
"   </p>",
"   <p>",
"    Definitive diagnosis of hereditary AT deficiency can be difficult because of the number of clinical disorders that can be associated with acquired AT deficiency (see below). Thus, while an AT level in the normal range is usually sufficient to exclude AT deficiency, low levels should be confirmed by obtaining another sample at a later time. Confirmation of the hereditary nature of the disorder requires the investigation of other family members. Diagnosis of other affected family members also permits appropriate counseling regarding the need for prophylaxis against venous thrombosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Plasma AT concentrations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean concentration of AT in normal pooled plasma is approximately 140",
"    <span class=\"nowrap\">",
"     &micro;g/mL.",
"    </span>",
"    The normal range of AT concentrations as determined by a functional-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor assay is reasonably narrow. Most laboratories report a normal range between 75 and 120 percent for AT-heparin cofactor determinations and a somewhat wider range for immunoassay results. Patients with AT deficiency usually have levels in the range of 40 to 60 percent.",
"   </p>",
"   <p>",
"    Healthy newborns have about one-half the normal adult AT concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/53,54\">",
"     53,54",
"    </a>",
"    ] and gradually reach the adult level by six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/55\">",
"     55",
"    </a>",
"    ]. The AT concentration may be considerably lower in infants born after 30 to 36 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/55\">",
"     55",
"    </a>",
"    ] and are even further reduced in infants with respiratory distress, necrotizing enterocolitis, sepsis, or disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thromboembolic events are rare in children with hereditary AT deficiency. In the absence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , AT contributes approximately 80 percent of the thrombin-neutralizing capacity of normal adult plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The plasma concentrations of a second thrombin inhibitor, alpha-2-macroglobulin, are higher during the first two decades of life than in adults, which may account for the lower risk of thromboembolic complications in AT-deficient patients during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acquired antithrombin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of pathophysiologic conditions lower the concentration of AT in the blood. There is no evidence that acquired AT deficiency contributes to increased thrombosis and there are no solid data supporting the use of AT replacement therapy in these conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are four general causes of acquired AT deficiency: accelerated consumption, reduced synthesis, increased losses, and drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Accelerated consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute thrombosis by itself can transiently reduce AT levels [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/62\">",
"     62",
"    </a>",
"    ]. During acute disseminated intravascular coagulation (DIC), for example, clotting factors and inhibitors are consumed faster than they can be replenished. The consumption of AT is significant in DIC and sepsis, and plasma AT levels predict outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major surgery is associated with a modest fall in AT levels which reaches a nadir around the third postoperative day, followed by an increase to normal at the fifth postoperative day [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/60\">",
"     60",
"    </a>",
"    ]. AT levels do not change substantially during normal pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/64,65\">",
"     64,65",
"    </a>",
"    ], but may decrease significantly in women with pregnancy-induced hypertension, preeclampsia, or eclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Reduced synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lowered AT concentrations occur in patients with liver disease (primarily cirrhosis) due to diminished protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. The clinical significance of this change is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Increased excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nephrotic syndrome is a hypercoagulable state associated with an increased incidence of venous and arterial thrombi. A variety of hemostatic abnormalities have been described including decreased AT levels due to urinary losses and perhaps to intravascular consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. There is, however, no convincing evidence that AT deficiency is responsible for the tendency to thrombosis in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=see_link\">",
"     \"Renal vein thrombosis and hypercoagulable state in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest reductions in plasma AT concentration are found in users of oral contraceptives and in individuals receiving estrogen for other purposes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/65,72\">",
"     65,72",
"    </a>",
"    ]. Infusions of L-asparaginase, a chemotherapeutic agent employed in the treatment of acute lymphocytic leukemia, can substantially lower the plasma concentration of AT by inhibition of protein synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/73\">",
"     73",
"    </a>",
"    ]. AT supplementation may suppress the procoagulant effects of L-asparaginase; however, the value of this approach is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=see_link\">",
"     \"Drug-induced thrombosis and vascular disease in patients with malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    decreases plasma AT levels, presumably via enhanced in vivo clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24136/abstract/52\">",
"     52",
"    </a>",
"    ]. Thus, as noted above, assays for AT should not be performed while the patient is taking heparin to avoid making an erroneous diagnosis of AT deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with AT deficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inherited thrombophilia\", section on 'Antithrombin deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11971705\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombin (AT), a natural anticoagulant, is a major inhibitor of thrombin and other coagulation serine proteases, including factors Xa and IXa. Augmentation of its inhibitory activity by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    constitutes the basis for the clinical use of heparin. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Physiology of antithrombin'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11971781\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;AT deficiency is usually inherited in an autosomal dominant fashion, with variable clinical penetrance, affecting both sexes equally. More than 127 different mutations of AT have been identified, which mostly occur in the heterozygous state. There are two types. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Genetics of antithrombin deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type I deficiency results from reduced synthesis of biologically normal protease inhibitor molecules. Antigenic and functional activity of AT in the blood are reduced in parallel to approximately 50 percent in heterozygotes.",
"     </li>",
"     <li>",
"      Type II deficiency is produced by a discrete molecular defect within AT. Functional activity is markedly reduced while antigenic activity is essentially normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11971830\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 60 percent of individuals with AT deficiency develop recurrent thrombotic episodes. Thrombotic episodes start to occur with some frequency after puberty, with a peak between 15 and 35 years of age. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11971877\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The AT-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor assay will detect all currently recognized subtypes of familial AT deficiency and is therefore the best single laboratory screening test for this disorder. An immunoassay in combination with the AT-heparin cofactor assay will then permit distinction between type I (reduced synthesis) and type II (reduced function) deficiency.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erroneous diagnoses can be made due to the influence of acute thrombosis, comorbid illness, or anticoagulant therapy on the concentrations of these plasma proteins.",
"     </li>",
"     <li>",
"      The AT-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      cofactor assay should be performed when the patient is off heparin, as heparin can lower AT levels by approximately 30 percent.",
"     </li>",
"     <li>",
"      A variety of pathophysiologic conditions lower the concentration of AT in the blood, namely accelerated consumption (eg, DIC), reduced synthesis (eg, liver disease), increased losses (eg, nephrotic syndrome), certain drugs (eg, L-asparaginase). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acquired antithrombin deficiency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11971926\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of patients with AT deficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inherited thrombophilia\", section on 'Antithrombin deficiency'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/1\">",
"      Mateo J, Oliver A, Borrell M, et al. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism--results of the Spanish Multicentric Study on Thrombophilia (EMET-Study). Thromb Haemost 1997; 77:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/2\">",
"      Margaglione M, Brancaccio V, Giuliani N, et al. Increased risk for venous thrombosis in carriers of the prothrombin G--&gt;A20210 gene variant. Ann Intern Med 1998; 129:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/3\">",
"      Khor B, Van Cott EM. Laboratory tests for antithrombin deficiency. Am J Hematol 2010; 85:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/4\">",
"      Zhou A, Huntington JA, Carrell RW. Formation of the antithrombin heterodimer in vivo and the onset of thrombosis. Blood 1999; 94:3388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/5\">",
"      Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/6\">",
"      Hirsh J. Heparin. N Engl J Med 1991; 324:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/7\">",
"      Fitches AC, Appleby R, Lane DA, et al. Impaired cotranslational processing as a mechanism for type I antithrombin deficiency. Blood 1998; 92:4671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/8\">",
"      Bock SC, Harris JF, Balazs I, Trent JM. Assignment of the human antithrombin III structural gene to chromosome 1q23-25. Cytogenet Cell Genet 1985; 39:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/9\">",
"      EGEBERG O. INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA. Thromb Diath Haemorrh 1965; 13:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/10\">",
"      Marciniak E, Farley CH, DeSimone PA. Familial thrombosis due to antithrombin 3 deficiency. Blood 1974; 43:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/11\">",
"      Carvalho A, Ellman L. Hereditary antithrombin III deficiency. Effect of antithrombin III deficiency on platelet function. Am J Med 1976; 61:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/12\">",
"      Mackie M, Bennett B, Ogston D, Douglas AS. Familial thrombosis: inherited deficiency of antithrombin III. Br Med J 1978; 1:136.",
"     </a>",
"    </li>",
"    <li>",
"     Bayston T, Lane D. Antithrombin mutation database, available at: www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin (Accessed on June 05, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/14\">",
"      Dahlb&auml;ck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/15\">",
"      Ambruso DR, Leonard BD, Bies RD, et al. Antithrombin III deficiency: decreased synthesis of a biochemically normal molecule. Blood 1982; 60:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/16\">",
"      Odeg&aring;rd OR, Abildgaard U. Antithrombin III: critical review of assay methods. Significance of variations in health and disease. Haemostasis 1978; 7:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/17\">",
"      Meade TW, Dyer S, Howarth DJ, et al. Antithrombin III and procoagulant activity: sex differences and effects of the menopause. Br J Haematol 1990; 74:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/18\">",
"      Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin III deficiency subtypes in 4000 healthy blood donors. Thromb Haemost 1992; 65:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/19\">",
"      Tait RC, Walker ID, Perry DJ, et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/20\">",
"      Lane DA, Mannucci PM, Bauer KA, et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/21\">",
"      Brunel F, Duchange N, Fischer AM, et al. Antithrombin III Alger: a new case of Arg 47----Cys mutation. Am J Hematol 1987; 25:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/22\">",
"      Ueyama H, Murakami T, Nishiguchi S, et al. Antithrombin III Kumamoto: identification of a point mutation and genotype analysis of the family. Thromb Haemost 1990; 63:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/23\">",
"      Picard V, Dautzenberg MD, Villoutreix BO, et al. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerization in vivo associated with severe childhood thrombosis. Blood 2003; 102:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/24\">",
"      Ambruso DR, Jacobson LJ, Hathaway WE. Inherited antithrombin III deficiency and cerebral thrombosis in a child. Pediatrics 1980; 65:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/25\">",
"      Cosgriff TM, Bishop DT, Hershgold EJ, et al. Familial antithrombin III deficiency: its natural history, genetics, diagnosis and treatment. Medicine (Baltimore) 1983; 62:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/26\">",
"      Bock SC, Harris JF, Schwartz CE, et al. Hereditary thrombosis in a Utah kindred is caused by a dysfunctional antithrombin III gene. Am J Hum Genet 1985; 37:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/27\">",
"      Bock SC, Marrinan JA, Radziejewska E. Antithrombin III Utah: proline-407 to leucine mutation in a highly conserved region near the inhibitor reactive site. Biochemistry 1988; 27:6171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/28\">",
"      Sas G, Blask&oacute; G, B&aacute;nhegyi D, et al. Abnormal antithrombin III (antithrombin III \"Budapest\") as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/29\">",
"      Olds RJ, Lane DA, Caso R, et al. Antithrombin III Budapest: a single amino acid substitution (429Pro to Leu) in a region highly conserved in the serpin family. Blood 1992; 79:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/30\">",
"      Hultin MB, McKay J, Abildgaard U. Antithrombin Oslo: type Ib classification of the first reported antithrombin-deficient family, with a review of hereditary antithrombin variants. Thromb Haemost 1988; 59:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/31\">",
"      Bock SC, Silberman JA, Wikoff W, et al. Identification of a threonine for alanine substitution at residue 404 of antithrombin III Oslo suggests integrity of the 404-407 region is important for maintaining normal plasma inhibitor levels. Thromb Haemost 1989; 62:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/32\">",
"      Demers C, Ginsberg JS, Hirsh J, et al. Thrombosis in antithrombin-III-deficient persons. Report of a large kindred and literature review. Ann Intern Med 1992; 116:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/33\">",
"      Finazzi G, Caccia R, Barbui T. Different prevalence of thromboembolism in the subtypes of congenital antithrombin III deficiency: review of 404 cases. Thromb Haemost 1987; 58:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/34\">",
"      Girolami A. The incidence of thrombotic manifestations in AT III abnormalities. Thromb Haemost 1987; 57:123.",
"     </a>",
"    </li>",
"    <li>",
"     Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. In: Clinics in Haematology, Prentice CR (Ed), Saunders, London 1981. Vol 10, p.369.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/36\">",
"      Maung R, Kelly JK, Schneider MP, Poon MC. Mesenteric venous thrombosis due to antithrombin III deficiency. Arch Pathol Lab Med 1988; 112:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/37\">",
"      Wilson C, Walker ID, Davidson JF, Imrie CW. Mesenteric venous thrombosis and antithrombin III deficiency. J Clin Pathol 1987; 40:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/38\">",
"      Bertram B, Remky A, Arend O, et al. Protein C, protein S, and antithrombin III in acute ocular occlusive diseases. Ger J Ophthalmol 1995; 4:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/39\">",
"      Ellis D. Recurrent renal vein thrombosis and renal failure associated with antithrombin-III deficiency. Pediatr Nephrol 1992; 6:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/40\">",
"      Daif A, Awada A, al-Rajeh S, et al. Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995; 26:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/41\">",
"      Das M, Carroll SF. Antithrombin III deficiency: an etiology of Budd-Chiari syndrome. Surgery 1985; 97:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/42\">",
"      Candrina R, Goppini A, Salvi A, et al. Arterial thrombosis in antithrombin III deficiency. Clin Lab Haematol 1986; 8:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/43\">",
"      Heijboer H, Brandjes DP, B&uuml;ller HR, et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/44\">",
"      Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/45\">",
"      Walker ID. Congenital thrombophilia. Baillieres Clin Obstet Gynaecol 1997; 11:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/46\">",
"      Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/47\">",
"      Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/48\">",
"      Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/49\">",
"      Wunderwald P, Schrenk WJ, Port H. Antithrombin BM from human plasma: an antithrombin binding moderately to heparin. Thromb Res 1982; 25:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/50\">",
"      Demers C, Henderson P, Blajchman MA, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost 1993; 69:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/51\">",
"      Michiels JJ, Hamuly&aacute;k K. Laboratory diagnosis of hereditary thrombophilia. Semin Thromb Hemost 1998; 24:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/52\">",
"      Marciniak E, Gockerman JP. Heparin-induced decrease in circulating antithrombin-III. Lancet 1977; 2:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/53\">",
"      McDonald MM, Hathaway WE, Reeve EB, Leonard BD. Biochemical and functional study of antithrombin III in newborn infants. Thromb Haemost 1982; 47:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/54\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/55\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/56\">",
"      Manco-Johnson MJ. Neonatal antithrombin III deficiency. Am J Med 1989; 87:49S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/57\">",
"      Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248:6490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/58\">",
"      Downing MR, Bloom JW, Mann KG. Comparison of the inhibition of thrombin by three plasma protease inhibitors. Biochemistry 1978; 17:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/59\">",
"      Mitchell L, Piovella F, Ofosu F, Andrew M. Alpha-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. Blood 1991; 78:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/60\">",
"      Lechner K, Kyrle PA. Antithrombin III concentrates--are they clinically useful? Thromb Haemost 1995; 73:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/61\">",
"      B&uuml;ller HR, ten Cate JW. Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications, and treatment with antithrombin III concentrate. Am J Med 1989; 87:44S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/62\">",
"      Damus PS, Wallace GA. Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy. Thromb Res 1975; 6:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/63\">",
"      Mammen EF. Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 1998; 24:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/64\">",
"      Panicucci F, Sagripanti A, Conte B, et al. Antithrombin III, heparin cofactor and antifactor Xa in relation to age, sex and pathological condition. Haemostasis 1980; 9:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/65\">",
"      Weenink GH, Kahl&eacute; LH, Lamping RJ, et al. Antithrombin III in oral contraceptive users and during normotensive pregnancy. Acta Obstet Gynecol Scand 1984; 63:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/66\">",
"      Weenink GH, Treffers PE, Vijn P, et al. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984; 148:1092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/67\">",
"      Raya-S&aacute;nchez JM, Gonz&aacute;lez-Reimers E, Rodr&iacute;guez-Mart&iacute;n JM, et al. Coagulation inhibitors in alcoholic liver cirrhosis. Alcohol 1998; 15:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/68\">",
"      Segal H, Cottam S, Potter D, Hunt BJ. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation. Hepatology 1997; 25:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/69\">",
"      Pirisi M, Fabris C, Ceriello A, et al. Deficient antithrombin III activity and enhanced fibrinolysis in patients with liver disease: evidence against a cause-effect relationship. Acta Gastroenterol Belg 1995; 58:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/70\">",
"      Kauffmann RH, Veltkamp JJ, Van Tilburg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med 1978; 65:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/71\">",
"      Chen TY, Huang CC, Tsao CJ. Hemostatic molecular markers in nephrotic syndrome. Am J Hematol 1993; 44:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/72\">",
"      Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/73\">",
"      Buchanan GR, Holtkamp CA. Reduced antithrombin III levels during L-asparaginase therapy. Med Pediatr Oncol 1980; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24136/abstract/74\">",
"      Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost 2003; 90:235.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1360 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.61.31.66-186E1AD1F7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24136=[""].join("\n");
var outline_f23_36_24136=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11971705\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHYSIOLOGY OF ANTITHROMBIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      GENETICS OF ANTITHROMBIN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Type II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Heparin binding site defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Thrombin binding site defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Pleiotropic defects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heparin resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Risk of deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSTIC ASSAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Timing of screening and effect of anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Plasma AT concentrations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acquired antithrombin deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Accelerated consumption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Reduced synthesis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Increased excretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11971705\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11971781\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11971830\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11971877\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11971926\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/36/6730?source=related_link\">",
"      Drug-induced thrombosis and vascular disease in patients with malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/12/3273?source=related_link\">",
"      Renal vein thrombosis and hypercoagulable state in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20903?source=related_link\">",
"      Screening for inherited thrombophilia in asymptomatic populations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_36_24137="Pegylated interferon (peginterferon) alfa-2b: Drug information";
var content_f23_36_24137=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pegylated interferon (peginterferon) alfa-2b: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/8/30854?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2b: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=see_link\">",
"    see \"Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F206966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      PegIntron&reg;;",
"     </li>",
"     <li>",
"      PegIntron&trade; Redipen&reg;;",
"     </li>",
"     <li>",
"      Sylatron&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F206967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PegIntron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F207002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Interferon",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F206970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Melanoma:",
"     </b>",
"     SubQ: 6 mcg/kg/week for 8 doses, followed by 3 mcg/kg/week for up to 5 years.",
"     <b>",
"      Note:",
"     </b>",
"     Premedicate with acetaminophen (500-1000 mg orally) 30 minutes prior to the first dose and as needed for subsequent doses thereafter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic hepatitis C (CHC):",
"     </b>",
"     SubQ: Administer dose once weekly;",
"     <b>",
"      Note:",
"     </b>",
"     Discontinue after 12 weeks in patients with HCV (genotype 1) if HCV RNA does not decrease by at least 2 log (compared to pretreatment) or if detectable HCV RNA present at 24. Discontinuation is also recommended in patients who previously failed therapy (regardless of genotype) if detectable HCV RNA present at 12 or 24 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Monotherapy",
"     </i>",
"     (duration of treatment is 1 year): Initial dose (based on average weekly dose of 1 mcg/kg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &le;45 kg: 40 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     46-56 kg: 50 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     57-72 kg: 64 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     73-88 kg: 80 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     89-106 kg: 96 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     107-136 kg: 120 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     137-160 kg: 150 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Combination therapy with ribavirin",
"     </i>",
"     (treatment duration is 48 weeks for genotype 1, 24 weeks for genotypes 2 and 3, or 48 weeks for patients who previously failed therapy [regardless of genotype]): Initial dose (based on an average weekly dose of 1.5 mcg/kg):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &lt;40 kg: 50 mcg once weekly (with ribavirin 800 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     40-50 kg: 64 mcg once weekly (with ribavirin 800 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     51-60 kg: 80 mcg once weekly (with ribavirin 800 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     61-65 kg: 96 mcg once weekly (with ribavirin 800 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     66-75 kg: 96 mcg once weekly (with ribavirin 1000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     76-80 kg: 120 mcg once weekly (with ribavirin 1000 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     81-85 kg: 120 mcg once weekly (with ribavirin 1200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     86-105 kg: 150 mcg once weekly (with ribavirin 1200 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;105 kg: 1.5 mcg/kg once weekly (with ribavirin 1400 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     <i>",
"      American Association for the Study of Liver Diseases (AASLD) guidelines recommendation:",
"     </i>",
"     Adults with chronic HCV infection: Treatment of choice: Ribavirin plus",
"     <b>",
"      peginterferon",
"     </b>",
"     ; clinical condition and ability of patient to tolerate therapy should be evaluated to determine length and/or likely benefit of therapy. Recommended treatment duration (AASLD guidelines; Ghany, 2009): Genotypes 1,4: 48 weeks; Genotypes 2,3: 24 weeks; Coinfection with HIV: 48 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6878383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=see_link\">",
"      see \"Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Chronic hepatitis C (CHC):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Manufacturer labeling:",
"     </i>",
"     Children &ge;3 years: SubQ: Combination therapy with ribavirin: 60 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly;",
"     <b>",
"      Note:",
"     </b>",
"     Children who reach their 18th birthday during treatment should remain on the pediatric regimen. Treatment duration is 48 weeks for genotype 1, 24 weeks for genotypes 2 and 3. Discontinue combination therapy in patients with HCV (genotype 1) at 12 weeks if HCV-RNA does not decrease by at least 2 log (compared to pretreatment) or if detectable HCV-RNA present at 24 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      American Association for the Study of Liver Diseases (AASLD) guideline recommendations (Ghany, 2009):",
"     </i>",
"     Children 2-17 years: SubQ: Treatment of choice: Peginterferon alfa-2b 60 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     once weekly in combination with oral ribavirin 15 mg/kg/day for 48 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F206971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F206972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic hepatitis C:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2b monotherapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-50 mL/minute: Reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10-29 mL/minute: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Reduce dose by 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Discontinue use if renal function declines during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2b combination with ribavirin:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children: Serum creatinine &gt;2 mg/dL: Discontinue treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute:  Combination therapy with ribavirin is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F206973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Decompensated liver disease or autoimmune hepatitis: Use is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic decompensation or severe hepatic injury during treatment (Child-Pugh score &gt;6 [class B or C]): Discontinue immediately.",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F207003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Melanoma:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Discontinue for any of the following:",
"     </b>",
"     Persistent or worsening severe neuropsychiatric disorders (depression, psychosis, encephalopathy), grade 4 nonhematologic toxicity, new or worsening retinopathy, new-onset ventricular arrhythmia or cardiovascular decompensation, evidence of hepatic injury (severe) or hepatic decompensation (Child-Pugh score &gt;6 [Class B or C]), development of hyper- or hypothyroidism or diabetes that cannot be effectively managed with medication, or inability to tolerate a dose of 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Temporarily withhold for any of the following:",
"     </b>",
"     ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ECOG performance status (PS) &ge;2, nonhematologic toxicity &ge; grade 3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     May reinitiate at a reduced dose once ANC &ge;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , ECOG PS at 0-1, and nonhematologic toxicity completely resolved or improved to grade 1.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Reduced dose schedule, Weeks 1-8:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First dose reduction (if prior dose 6 mcg/kg/week): 3 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose reduction (if prior dose 3 mcg/kg/week): 2 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Third dose reduction (if prior dose 2 mcg/kg/week): 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Discontinue permanently if unable to tolerate 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Reduced dose schedule, Weeks 9-260:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     First dose reduction (if prior dose 3 mcg/kg/week): 2 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Second dose reduction (if prior dose 2 mcg/kg/week): 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Discontinue permanently if unable to tolerate 1 mcg/kg/week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Chronic hepatitis C:",
"      </i>",
"     </b>",
"     <b>",
"      Dosage adjustment for depression (severity based upon DSM-IV criteria):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Mild depression:",
"     </i>",
"     No dosage adjustment required; evaluate once weekly by visit/phone call. If depression remains stable, continue weekly visits. If depression improves, resume normal visit schedule. For worsening depression, see &ldquo;Moderate depression&rdquo; or &ldquo;Severe depression&rdquo; below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Moderate depression:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Evaluate once weekly (visit or phone) with an office visit at least every other week. If depression remains stable, consider psychiatric evaluation and continue with reduced dosing. If symptoms improve and remain stable for 4 weeks, resume normal visit schedule; continue reduced dosing or return to normal dose. For worsening depression, see &ldquo;Severe depression&rdquo; below.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children: Decrease peginterferon alfa-2b dose to 40 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week, may further decrease to 20 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction with monotherapy for depression below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction with combination therapy for depression below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Severe depression:",
"     </i>",
"     Discontinue peginterferon alfa-2b and ribavirin permanently. Obtain immediate psychiatric consultation. Utilize followup psychiatric therapy as needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Chronic hepatitis C:",
"      </i>",
"     </b>",
"     <b>",
"      Dosage adjustment in hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hemoglobin decrease &ge;2 g/dL in any 4-week period in patients with pre-existing cardiac disease: Monitor and evaluate weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL: Decrease ribavirin dose to 12 mg/kg/day; may further reduce to 8 mg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     WBC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;70,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Reduce peginterferon alfa-2b dose to 40 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week; may further reduce to 20 mcg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL, WBC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Permanently discontinue peginterferon alfa-2b and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hemoglobin decrease &gt;2 g/dL in any 4-week period and stable cardiac disease: Decrease peginterferon alfa-2b dose by 50%; decrease ribavirin dose by 200 mg/day. Hemoglobin &lt;12 g/dL after dose reductions: Permanently discontinue both peginterferon alfa-2b and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hemoglobin &lt;10 g/dL in patients with cardiac disease: Reduce peginterferon alfa-2b dose by 50%; decrease ribavirin dose by 200 mg/day (patients receiving 1400 mg/day should decrease dose by 400 mg/day [ie, first dose reduction to 1000 mg/day]); may further reduce ribavirin dose by additional 200 mg/day if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     WBC &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2b monotherapy: Refer to adult weight-based dosage reduction monotherapy for hematologic toxicity below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Peginterferon alfa-2b combination therapy: Refer to adult weight-based dosage reduction with combination therapy for hematologic toxicity below",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Hemoglobin &lt;8.5 g/dL, WBC &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , neutrophils &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     , or platelets &lt;25,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     : Permanently discontinue peginterferon alfa-2b and ribavirin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Chronic hepatitis C:",
"      </i>",
"     </b>",
"     <b>",
"      Adult weight-based dosage reduction for depression or hematologic toxicity:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Peginterferon alfa-2b monotherapy:",
"     </i>",
"     Reduce to average weekly dose of 0.5 mcg/kg as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &le;45 kg: 20 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     46-56 kg: 25 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     57-72 kg: 30 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     73-88 kg:  40 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     89-106 kg: 50 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     107-136 kg: 64 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &ge;137 kg: 80 mcg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Peginterferon alfa-2b combination therapy:",
"     </i>",
"     Initially reduce to average weekly dose of 1 mcg/kg; may further reduce to average weekly dose of 0.5 mcg/kg if needed as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &lt;40 kg: 35 mcg once weekly; may further reduce to 20 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     40-50 kg: 45 mcg once weekly; may further reduce to 25 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     51-60 kg: 50 mcg once weekly; may further reduce to 30 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     61-75 kg: 64 mcg once weekly; may further reduce to 35 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     76-85 kg: 80 mcg once weekly; may further reduce to 45 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     86-104 kg: 96 mcg once weekly; may further reduce to 50 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     105-125 kg: 108 mcg once weekly; may further reduce to 64 mcg once weekly if needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     &gt;125 kg: 135 mcg once weekly; may further reduce to 72 mcg once weekly if needed",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F206945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sylatron&trade;: 296 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sylatron&trade;: 444 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sylatron&trade;: 888 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PegIntron&reg;: 50 mcg, 80 mcg, 120 mcg, 150 mcg [contains polysorbate 80, sucrose 59.2 mg; supplied with diluent]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PegIntron&trade; Redipen&reg;: 50 mcg, 80 mcg, 120 mcg, 150 mcg [contains polysorbate 80, sucrose 54 mg; supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F206930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     PegIntron&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133677.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133677.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     PegIntron&reg; Redipen&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133675.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM133675.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Sylatron&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249397.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM249397.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F206947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For SubQ administration; rotate injection site; thigh, outer surface of upper arm, and abdomen are preferred injection sites; do not inject near navel or waistline; patients who are thin should only use thigh or upper arm. Do not inject into bruised, infected, irritated, red, or scarred skin. The weekly dose may be administered at bedtime to reduce flu-like symptoms. For the treatment of CHC, the administration volume depends on the patient&rsquo;s weight and the peginterferon concentration used.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F207009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with any other medicines.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F206946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PegIntron&reg;: Treatment of chronic hepatitis C (CHC; in combination with ribavirin) in patients who have compensated liver disease; treatment of chronic hepatitis C (as monotherapy) in adult patients with compensated liver disease who have never received alfa interferons and are intolerant to ribavirin or have contraindications to ribavirin.",
"     <b>",
"      Note:",
"     </b>",
"     Combination therapy with ribavirin provides better response rates than peginterferon monotherapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sylatron&trade;: Adjuvant treatment of melanoma (with microscopic or gross nodal involvement within 84 days of definitive surgical resection, including complete lymphadenectomy)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5367712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Peginterferon alfa-2b may be confused with interferon alfa-2a, interferon alfa-2b, interferon alfa-n3, peginterferon alfa-2a",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       PegIntron&reg; may be confused with Intron&reg; A, Pegasys&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Peginterferon alfa-2b may be confused with interferon alpha multi-subtype which is available in international markets",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F207000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Percentages reported for adults receiving monotherapy unless noted:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (52% to 94%), fever (22% to 75%), headache (56% to 70%), chills (&le;63%), depression (29% to 59%; may be severe), dizziness (12% to 35%), anxiety/emotional liability/irritability (28%), insomnia (23%), olfactory nerve disorder (&le;23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (6% to 36%), alopecia (22% to 34%), pruritus (12%), dry skin (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Anorexia (20% to 69%), nausea (26% to 64%), taste perversion (&le;38%), diarrhea (18% to 37%), vomiting (7% to 26%), abdominal pain (8% to 15%), weight loss (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (6% to 70%; grade 4: 1%), thrombocytopenia (7% to 20%; grades 3/4: &lt;4%), anemia (6%; in combination with ribavirin: 12% to 47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: ALT/AST increased (10% to 77%), alkaline phosphatase increased (&le;23%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site inflammation/reaction (23% to 62%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (54% to 68%), weakness (52%), arthralgia (23% to 51%), musculoskeletal pain (28%), rigors (23%), paresthesia (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Binding antibodies (melanoma patients 35%), viral infection (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (6%), flushing (6%), bundle branch block (4%), myocardial infarction (4%), supraventricular arrhythmia (4%), ventricular tachycardia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Concentration impaired (10%), malaise (7%), nervousness (4%), agitation (2%), suicidal behavior (ideation/attempt/suicide &le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypothyroidism (5%), menstrual disorder (4%), hyperthyroidism (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (6%), xerostomia (6%), constipation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: GGT increased (8%), hepatomegaly (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site pain (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (4%), blurred vision (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Proteinuria (&le;7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (10%), cough (5% to 8%), sinusitis (7%), dyspnea (4% to 6%), rhinitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (6%), neutralizing antibodies (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important and life-threatening): Addiction (drug) relapse, anaphylaxis, angina, angioedema, aphthous stomatitis, aplastic anemia, arrhythmia, autoimmune thrombocytopenia (with or without purpura), bacterial infection, bipolar disorders, blindness, bronchiolitis obliterans, cardiac arrest, cardiomyopathy, cellulitis, colitis, cotton wool spots, cytopenia, diabetes mellitus, diabetic ketoacidosis, drug overdose, emphysema, encephalopathy, erythema multiforme, fungal infection, gastroenteritis, gout, hallucinations, hearing impairment/loss, hemorrhagic colitis, homicidal ideation, hyperglycemia, hyper-/hypotension, hypersensitivity reactions, hypertriglyceridemia, injection site necrosis, interstitial nephritis, interstitial pneumonitis, ischemic colitis, leukopenia, loss of consciousness, lupus-like syndrome, macular edema, mania, memory loss, migraine, myositis, nerve palsy (facial/oculomotor), optic neuritis, palpitation, pancreatitis, papilledema, pericardial effusion, peripheral neuropathy, phototoxicity, pleural effusion, pneumonia, psoriasis, psychosis, pulmonary hypertension, pulmonary infiltrates, pure red cell aplasia, renal failure, renal insufficiency, retinal artery or vein thrombosis, retinal detachment (serous), retinal hemorrhage, retinal ischemia, retinopathy, rhabdomyolysis, rheumatoid arthritis, sarcoidosis, seizure, sepsis, serum creatinine increased, Stevens-Johnson syndrome, stroke, systemic lupus erythematosus, tachycardia, thrombotic thrombocytopenic purpura, thyroiditis, toxic epidermal necrolysis, transient ischemic attack, ulcerative colitis, vasculitis, vision decrease/loss, Vogt-Koyanagi-Harada syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F206950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity (including urticaria, angioedema, bronchoconstriction, anaphylaxis, Stevens Johnson syndrome and toxic epidermal necrolysis) to peginterferon alfa-2b, interferon alfa-2b, other alfa interferons, or any component of the formulation; autoimmune hepatitis; decompensated liver disease (Child-Pugh score &gt;6, classes B and C)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Combination therapy with peginterferon alfa-2b and ribavirin is also contraindicated in pregnancy, women who may become pregnant, males with pregnant partners; hemoglobinopathies (eg, thalassemia major, sickle-cell anemia); renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F206934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: Causes bone marrow suppression, including potentially severe cytopenias; alfa interferons may (rarely) cause aplastic anemia. Use with caution in patients who are chronically immunosuppressed, with low peripheral blood counts or myelosuppression, including concurrent use of myelosuppressive therapy. Dosage modification may be necessary for hematologic toxicity. Combination therapy with ribavirin may potentiate the neutropenic effects of alfa interferons. When used in combination with ribavirin, an increased incidence of anemia was observed when using ribavirin weight-based dosing, as compared to flat-dose ribavirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Colitis: Ulcerative or hemorrhagic/ischemic colitis has been observed with alfa interferons (within 12 weeks of initiation); discontinue therapy if signs of colitis (abdominal pain, bloody diarrhea, fever) develop; symptoms typically resolve within 1-3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dental/periodontal disorders: Have been reported with combination therapy; dry mouth may affect teeth and mucous membranes. Instruct patients to brush teeth twice daily; encourage regular dental exams. Rinse mouth thoroughly after vomiting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Flu-like symptoms: Interferons are commonly associated with flu-like symptoms. Use with caution in patients with debilitating conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Acute hypersensitivity reactions (eg, urticaria, angioedema, bronchoconstriction, anaphylaxis) and cutaneous reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (rarely) with alfa interferons; prompt discontinuation and management is recommended. Transient rashes do not require interruption of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertriglyceridemia: Has been reported (may result in pancreatitis); periodically monitor and manage with appropriate treatment; consider discontinuing peginterferon if persistent and severe (triglycerides &gt;1000 mg/dL), particularly if combined with symptoms of pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropsychiatric disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate severe depression or other neuropsychiatric adverse events (including suicide and suicidal ideation) in patients with and without a history of psychiatric disorder; monitor closely with clinical evaluations (periodic). Discontinue treatment with worsening or persistently severe signs/symptoms of neuropsychiatric disorders (eg, depression, encephalopathy, psychosis). Many cases resolve upon discontinuation, although some cases may persist.",
"     </b>",
"     Addiction relapse, aggression, depression, homicidal ideation and suicidal behavior/ideation have been observed with peginterferon alfa-2b; bipolar disorder, encephalopathy, hallucinations, mania, and psychosis have been observed with other alfa interferons. Onset may be delayed (up to 6 months after discontinuation). Higher doses may be associated with the development of encephalopathy (higher risk in elderly patients). Use with caution in patients with a history of psychiatric disorders, including depression or substance abuse history. New or exacerbated neuropsychiatric or substance abuse disorders are best managed with early intervention. Drug screening and periodic health evaluation (including monitoring of psychiatric symptoms) is recommended if initiating treatment in patients with coexisting psychiatric condition or substance abuse disorders. Monitor all patients for evidence of depression and other psychiatric symptoms; patients being treated for melanoma should be monitored for depression and psychiatric symptoms every 3 weeks during the first 8 weeks of treatment and every 6 months thereafter and permanently discontinue treatment if psychiatric symptoms persist, worsen or if suicidal behavior develops. Patients should continue to be monitored for 6 months after completion of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic effects: Ophthalmologic disorders (including decreased visual acuity, blindness, macular edema, retinal hemorrhages, optic neuritis, papilledema, cotton wool spots, retinal detachment [serous], and retinal artery or vein thrombosis) have occurred with peginterferon alfa-2b and/or with other alfa interferons. Prior to start of therapy, ophthalmic exams are recommended for all patients; patients with diabetic or hypertensive retinopathy should have periodic ophthalmic exams during treatment; a complete eye exam should be done promptly in patients who develop ocular symptoms. Permanently discontinue treatment with new or worsening ophthalmic disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pancreatitis: Pancreatitis, including fatal cases, has been observed with alfa interferon therapy; withhold treatment for suspected pancreatitis; discontinue therapy for known  pancreatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary effects: May cause or aggravate dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis obliterans, interstitial pneumonitis, pulmonary hypertension, and sarcoidosis which may result in respiratory failure; may recur upon rechallenge with treatment; monitor closely. Use with caution in patients with existing pulmonary disease (eg, chronic obstructive pulmonary disease). Withhold combination therapy with ribavirin for development of pulmonary infiltrate or pulmonary function impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disease:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or exacerbate autoimmune disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment in patients with worsening or persistently severe signs/symptoms of autoimmune disease; may resolve with discontinuation.",
"     </b>",
"     Thyroiditis, thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura, rheumatoid arthritis, interstitial nephritis, systemic lupus erythematosus, and psoriasis have been reported with therapy; use with caution in patients with autoimmune disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or a history of cardiovascular disease; hypotension, arrhythmia, bundle branch block, tachycardia, cardiomyopathy, angina pectoris and MI have been observed with treatment. Patients with pre-existing cardiac abnormalities should have baseline ECGs prior to combination treatment with ribavirin; closely monitor patients with a history of MI or arrhythmia. Patients with a history of significant or unstable cardiac disease should not receive combination treatment with ribavirin. Discontinue treatment (permanently) for new-onset ventricular arrhythmia or cardiovascular decompensation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Diabetes mellitus (including new-onset type I diabetes) and hyperglycemia have been reported; discontinue if diabetes cannot be effectively managed with medication. Use with caution in patients with a history of diabetes mellitus, particularly if prone to DKA.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use is contraindicated in patients with hepatic decompensation or autoimmune hepatitis. Discontinue treatment immediately with hepatic decompensation (Child Pugh score &gt;6) or evidence of severe hepatic injury. Patients with chronic hepatitis C (CHC) with cirrhosis and patients coinfected with human immunodeficiency virus (HIV) receiving highly-active antiretroviral therapy (HAART) are at increased risk for hepatic decompensation; monitor closely. A transient increase in ALT (2-5 times above baseline) which is not associated with liver dysfunction may occur with peginterferon alfa-2b use (for the treatment of chronic hepatitis C); may continue treatment with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infectious disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate infectious disorders; monitor closely with clinical and lab evaluations (periodic); discontinue treatment in patients with worsening or persistently severe signs/symptoms of infectious disorders; may resolve with discontinuation.",
"     </b>",
"     Interferon therapy is commonly associated with flu-like symptoms, including fever; rule out other causes/infection with persistent or high fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ischemic disorders:",
"     <b>",
"      [U.S. Boxed Warning]: May cause or aggravate ischemic and hemorrhagic cerebrovascular events; monitor closely with clinical and lab evaluations (periodic); discontinue treatment in patients with worsening or persistent ischemia; may resolve with discontinuation.",
"     </b>",
"     Have been reported in patients without risk factors for stroke.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); monitor closely for signs of interferon toxicity. For the treatment of chronic hepatitis C, dosage adjustments are recommended with monotherapy in patients with moderate-to-severe impairment; do not use combination therapy with ribavirin in adults with renal dysfunction (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute); discontinue if serum creatinine &gt;2 mg/dL in children. Has not been studied in melanoma patients with renal impairment. Serum creatinine increases have been reported in patients with renal insufficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disorders: Use with caution in patients with thyroid disorders; may cause or aggravate hyper- or hypothyroidism. Discontinue use in patients with thyroid disease who cannot be controlled with medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Combination therapy with ribavirin:",
"     <b>",
"      [U.S. Boxed Warning]: Combination treatment with ribavirin may cause birth defects and/or fetal mortality, hemolytic anemia (which may worsen cardiac disease), genotoxicity, mutagenicity, and may possibly be carcinogenic.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; the potential adverse effects (eg, neuropsychiatric events, cardiac events, systemic effects) may be more pronounced. Encephalopathy has also been observed in primarily elderly patients treated with higher doses of peginterferon alfa-2b. For the treatment of hepatitis, elderly patients generally do not respond to interferon treatment as well as younger patients. When used in combination with ribavirin, closely monitor adults &gt;50 years of age for the development of anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Growth velocity (height and weight) was decreased in children on combination treatment with ribavirin, particularly during the first 6 months of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients.",
"     </b>",
"     Combination therapy with ribavirin is contraindicated in pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product variability:",
"     <b>",
"      Due to differences in dosage, patients should not change brands of interferon.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Combination therapy with ribavirin is preferred over monotherapy for the treatment of chronic hepatitis C. Safety and efficacy have not been established in patients who have received organ transplants or are coinfected with HIV or hepatitis B. Patients with significant bridging fibrosis or cirrhosis, genotype 1 infection or who have not responded to prior therapy, including previous pegylated interferon treatment are less likely to benefit from combination therapy with peginterferon alfa-2b and ribavirin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F206997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F206938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Interferons (Alfa) may enhance the adverse/toxic effect of Aldesleukin. In particular, risks of myocardial and renal toxicity may be increased by this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: Peginterferon Alfa-2b may decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: Peginterferon Alfa-2b may decrease the serum concentration of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Betaxolol (Ophthalmic); Carteolol (Ophthalmic); Timolol (Ophthalmic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FLUoxetine: Peginterferon Alfa-2b may decrease the serum concentration of FLUoxetine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Interferons (Alfa) may increase the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegloticase: May diminish the therapeutic effect of Peginterferon Alfa-2b.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: Interferons (Alfa) may enhance the adverse/toxic effect of Ribavirin. Hemolytic anemia has been observed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telbivudine: Peginterferon Alfa-2b may enhance the adverse/toxic effect of Telbivudine. Specifically, the risk for peripheral neuropathy may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Interferons may decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Interferons may enhance the adverse/toxic effect of Zidovudine. Interferons may decrease the metabolism of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F206962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid use in patients with hepatitis C virus.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F206940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C / X in combination with ribavirin (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F206952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies with pegylated interferon alfa have not been conducted. Animal reproduction studies with nonpegylated interferon alfa-2b have demonstrated abortifacient effects. Disruption of the normal menstrual cycle was also observed in animal studies; therefore, the manufacturer recommends that reliable contraception is used in women of childbearing potential. Alfa interferon is endogenous to normal amniotic fluid.",
"     <i>",
"      In vitro",
"     </i>",
"     administration studies have reported that when administered to the mother, it does not cross the placenta. Case reports of use in pregnant women are limited. The Perinatal HIV Guidelines Working Group does not recommend that peginterferon alfa be used during pregnancy. Peginterferon alfa-2b monotherapy should only be used in pregnancy when the potential benefit to the mother justifies the possible risk to the fetus.",
"     <b>",
"      [U.S. Boxed Warning]: Combination therapy with ribavirin may cause birth defects and/or fetal mortality; avoid pregnancy in females and female partners of male patients;",
"     </b>",
"     combination therapy with ribavirin is contraindicated in pregnancy. Two forms of contraception should be used during combination therapy; patients should have monthly pregnancy tests. A pregnancy registry has been established for women inadvertently exposed to ribavirin while pregnant (800-593-2214).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F206974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F206953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Breast milk samples obtained from a lactating mother prior to and after administration of interferon alfa-2b showed that interferon alfa is present in breast milk and administration of the medication did not significantly affect endogenous levels. Breast-feeding is not linked to the spread of hepatitis C virus; however, if nipples are cracked or bleeding, breast-feeding is not recommended. Mothers coinfected with HIV are discouraged from breast-feeding to decrease potential transmission of HIV.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2883315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Peg-Intron Redipen Pak 4 Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/0.5 mL (4): $2952.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mcg/0.5 mL (4): $3099.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mcg/0.5 mL (4): $3254.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg/0.5 mL (4): $3417.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Peg-Intron Redipen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/0.5 mL (1): $738.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mcg/0.5 mL (1): $774.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mcg/0.5 mL (1): $813.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg/0.5 mL (1): $854.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Peg-Intron Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mcg/0.5 mL (1): $738.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mcg/0.5 mL (1): $774.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mcg/0.5 mL (1): $813.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mcg/0.5 mL (1): $854.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Sylatron Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 X 296 mcg (1): $5260.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 X 444 mcg (1): $7891.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 X 888 mcg (1): $15783.01",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     296 mcg (1): $1315.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     444 mcg (1): $1972.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     888 mcg (1): $3945.76",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F206942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic TSH (for patients being treated for melanoma, obtain baseline within 4 weeks prior to treatment initiation, and then at 3 and 6 months, and every 6 months thereafter during treatment); CBC with differential and platelets; serum chemistries, liver function tests  (for patients with melanoma, monitor serum bilirubin, ALT, AST, alkaline phosphatase, and LDH at 2 and 8 weeks, and 2 and 3 months following initiation, then every 6 months during therapy), renal function, triglycerides; serum glucose or Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     (for patients with diabetes mellitus). Clinical studies (for combination therapy) tested as follows: CBC (including hemoglobin, WBC, and platelets) and chemistries (including liver function tests and uric acid) measured at weeks 2, 4, 8, and 12, and then every 6 weeks; TSH measured every 12 weeks during treatment. ECG at baseline for patients with pre-existing cardiac abnormalities (for combination therapy with ribavirin).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hepatitic C: Serum HCV RNA levels (pretreatment, 12 and 24 weeks after therapy initiation, 24 weeks after completion of therapy).",
"     <b>",
"      Note:",
"     </b>",
"     Discontinuation of therapy may be considered after 12 weeks in patients with HCV (genotype 1) who fail to achieve an early virologic response (EVR) (defined as &ge;2-log decrease in HCV RNA compared to pretreatment) or after 24 weeks with detectable HCV RNA. Treat patients with HCV (genotypes 2,3) for 24 weeks (if tolerated) and then evaluate HCV RNA levels (Ghany, 2009).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Evaluate for depression and other psychiatric symptoms before and after initiation of therapy; patients being treated for melanoma should be monitored for depression and psychiatric symptoms every 3 weeks during the first eight weeks of treatment and every 6 months thereafter, and continued monitoring for 6 months after the last dose; baseline ophthalmic eye examination; periodic ophthalmic exam in patients with diabetic or hypertensive retinopathy; baseline ECG in patients with cardiac disease; serum glucose or Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     (for patients with diabetes mellitus). In combination therapy with ribavirin, pregnancy tests (for women of childbearing age who are receiving treatment or who have male partners who are receiving treatment), continue monthly up to 6 months after discontinuation of therapy.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F206954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      PEG-Intron (AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, EE, ES, FI, FR, GR, GT, HN, ID, IE, IL, IT, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE);",
"     </li>",
"     <li>",
"      Pegtron (MX);",
"     </li>",
"     <li>",
"      ViraFeronPEG (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F206933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alpha interferons are a family of proteins, produced by nucleated cells, that have antiviral, antiproliferative, and immune-regulating activity. There are 16 known subtypes of alpha interferons. Interferons interact with cells through high affinity cell surface receptors. Following activation, multiple effects can be detected including induction of gene transcription. Inhibits cellular growth, alters the state of cellular differentiation, interferes with oncogene expression, alters cell surface antigen expression, increases phagocytic activity of macrophages, and augments cytotoxicity of lymphocytes for target cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F206949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Increases with chronic dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: CHC: ~40 hours (range: 22-60 hours); Melanoma: ~43-51 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: CHC: 15-44 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~30%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 86: &ldquo;Viral Hepatitis in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2007, 110(4):941-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/17906043/pubmed\" id=\"17906043\" target=\"_blank\">",
"        17906043",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bottomley A, Coens C, Suciu S, et al, &ldquo;Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(18):2916-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/19433686/pubmed\" id=\"19433686\" target=\"_blank\">",
"        19433686",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bouwhuis MG, Suciu S, Testori A, et al, \"Phase III Trial Comparing Adjuvant Treatment With Pegylated Interferon Alfa-2b Versus Observation: Prognostic Significance of Autoantibodies--EORTC 18991,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2010, 28(14):2460-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/20385998/pubmed\" id=\"20385998\" target=\"_blank\">",
"        20385998",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dienstag JL and McHutchinson JG, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Hepatitis C,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 130(1):225-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/16401485/pubmed\" id=\"16401485\" target=\"_blank\">",
"        16401485",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eggermont AM, Suciu S, Santinami M, et al, \"Adjuvant Therapy With Pegylated Interferon Alfa-2b versus Observation Alone in Resected Stage III Melanoma: Final Results of EORTC 18991, A Randomised Phase III Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 372(9633):117-26",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/18620949/pubmed\" id=\"18620949\" target=\"_blank\">",
"        18620949",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Eggermont AM, Suciu S, Testori A, et al, &ldquo;Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b versus Observation in Resected Stage III Melanoma,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(31):3810-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/23008300/pubmed\" id=\"23008300\" target=\"_blank\">",
"        23008300",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Nelson DR, Strader DB, et al, &ldquo;An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection:  2011 Practice Guideline by the American Association for the Study of Liver Diseases,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2011, 54(4):1433-44.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/21898493/pubmed\" id=\"21898493\" target=\"_blank\">",
"        21898493",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ghany MG, Strader DB, Thomas DL, et al, &ldquo;Diagnosis, Management And Treatment Of Hepatitis C: An Update,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2009, 49(4):1335-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/19330875/pubmed\" id=\"19330875\" target=\"_blank\">",
"        19330875",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamnvik OP, Larsen PR, and Marqusee E, &ldquo;Thyroid Dysfunction From Antineoplastic Agents,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2011, 103(21):1572-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/22010182/pubmed\" id=\"22010182\" target=\"_blank\">",
"        22010182",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heathcote EJ, Shiffman ML, Cooksley GE, et al, &ldquo;Peginterferon Alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343:1673-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/11106716/pubmed\" id=\"11106716\" target=\"_blank\">",
"        11106716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar AR, Hale TW, and Moke RE, &ldquo;Transfer of Interferon Alfa Into Human Breast Milk,&rdquo;",
"      <i>",
"       J Hum Lact",
"      </i>",
"      , 2000, 16:226-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/11153157/pubmed\" id=\"11153157\" target=\"_blank\">",
"        11153157",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lebon P, Girard S, Thepot F, et al, &ldquo;The Presence of Alpha-Interferon in Human Amniotic Fluid,&rdquo;",
"      <i>",
"       J Gen Virol",
"      </i>",
"      , 1982, 59(Pt 2):393-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/6176680/pubmed\" id=\"6176680\" target=\"_blank\">",
"        6176680",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McHutchison JG, Lawitz EJ, Shiffman ML, et al, &ldquo;Peginterferon Alfa-2b or Alfa-2a With Ribavirin for Treatment of Hepatitis C Infection,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 361(6):580-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/19625712/pubmed\" id=\"19625712\" target=\"_blank\">",
"        19625712",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,&rdquo; April 29, 2009, 1-90. Available at",
"      <a href=\"file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Poynard T, Colombo M, Bruix J, et al, &ldquo;Peginterferon Alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon Alfa/Ribavirin Therapy,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2009, 136(5):1618-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/19208349/pubmed\" id=\"19208349\" target=\"_blank\">",
"        19208349",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spieth K, Kaufmann R, Dummer R, et al, &ldquo;Temozolomide Plus Pegylated Interferon Alfa-2b as First-Line Treatment for Stage IV Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group (DeCOG),&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2008, 19(4):801-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/18178958/pubmed\" id=\"18178958\" target=\"_blank\">",
"        18178958",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Waysbort A, Giroux M, Mansat V, et al, &ldquo;Experimental Study of Transplacental Passage of Alpha Interferon by Two Assay Techniques,&rdquo;",
"      <i>",
"       Antimicrob Agents Chemother",
"      </i>",
"      , 1993, 37(6):1232-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/36/24137/abstract-text/8328774/pubmed\" id=\"8328774\" target=\"_blank\">",
"        8328774",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9976 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24137=[""].join("\n");
var outline_f23_36_24137=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709198\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206966\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206967\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207002\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206970\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6878383\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206971\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206972\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206973\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207003\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206945\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206930\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874942\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206947\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207009\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206946\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5367712\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207000\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206950\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206934\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206997\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206938\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206962\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206940\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206952\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206974\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206953\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2883315\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206942\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206954\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206933\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F206949\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9976\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9976|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/8/30854?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/12/38088?source=related_link\">",
"      Pegylated interferon (peginterferon) alfa-2b: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_36_24138="Diagnostic evaluation of women with suspected breast cancer";
var content_f23_36_24138=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic evaluation of women with suspected breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Laura J Esserman, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Bonnie N Joe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/36/24138/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/36/24138/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 230,480 American women are diagnosed with breast cancer annually, and 39,520 women die from this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/1\">",
"     1",
"    </a>",
"    ]. Global cancer statistics show that breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23 percent of total cancer cases and 14 percent of cancer deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/2\">",
"     2",
"    </a>",
"    ]. Breast cancer is now also the leading cause of cancer death among females in economically developing countries.",
"   </p>",
"   <p>",
"    Despite increasing incidence rates, annual mortality rates from breast cancer have decreased over the last decade (1.8 percent per year from 1998 to 2007) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/3\">",
"     3",
"    </a>",
"    ]. The decline has been more pronounced in Caucasian than in African-American women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant portion of the decline in mortality is attributable to the impact of screening mammography, which permits diagnosis at an earlier stage of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/4\">",
"     4",
"    </a>",
"    ]. Preinvasive breast cancer (ductal carcinoma in situ, DCIS) now accounts for 25 to 30 percent of all newly diagnosed, mammographically detected breast cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link&amp;anchor=H556311124#H556311124\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\", section on 'Mammographic screening'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of breast cancers are diagnosed as a result of an abnormal mammogram, but not all mammographic findings represent cancer. Women who have an abnormal screening mammogram often need further diagnostic evaluation with magnification views, spot compression views",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    targeted ultrasonography to determine the need for tissue sampling or biopsy. Additionally, not all cancers are detectable on mammography. A clinically suspicious mass should also be biopsied, regardless of imaging findings, as about 15 percent of such lesions can be mammographically occult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/5\">",
"     5",
"    </a>",
"    ]. The goal of the initial biopsy is to obtain sufficient diagnostic material using the least invasive approach and to avoid surgical excision of benign lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This review will discuss the diagnostic evaluation and management of a woman with suspected breast cancer due to either abnormal imaging or physical findings. Initial staging work-up of patients with newly diagnosed breast cancer, the general approach to evaluation of breast masses in women, and breast biopsy techniques are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPORTANCE OF MULTIDISCIPLINARY CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A suspicion of breast cancer requires that care be coordinated among clinicians in several specialties. An integrated approach with breast imagers and breast surgeons can minimize unnecessary biopsies and expedite diagnosis for the woman who receives a diagnosis of breast cancer. Similarly, once the diagnosis of cancer is made, multidisciplinary coordination among breast and reconstructive surgeons, radiation and medical oncologists, radiologists and pathologists facilitates treatment planning and streamlines patient care [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MAMMOGRAMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of breast cancers are associated with abnormal mammographic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. As an example, in the Breast Cancer Detection Demonstration Project (BCDDP), fewer than 10 percent of cancers were detected solely by physical examination and over 90 percent were identified mammographically [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If an abnormality is found at mammographic screening, supplemental mammographic views and possibly ultrasound should be used for further characterization. A variety of mammographic techniques, including spot compression and magnification views (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74424 \" href=\"UTD.htm?35/35/36400\">",
"     image 1",
"    </a>",
"    ) and varied angled views, may characterize a lesion more precisely prior to making a final recommendation for management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H27#H27\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'Diagnostic mammogram'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some of the most aggressive cancers appear between normal screening mammograms and are therefore termed interval cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/9\">",
"     9",
"    </a>",
"    ]. Younger women may present with large tumors prior to the age at which screening is usually recommended. Accordingly, when women present with a suspicious new mass, diagnostic mammograms should be part of the initial workup, despite young age or having had a negative routine screening mammogram.",
"   </p>",
"   <p>",
"    Diagnostic mammography is associated with higher sensitivity but lower specificity as compared to screening mammography. In one prospective study of women with signs or symptoms of breast cancer, 15 percent (6279 of 41,427) of diagnostic mammograms were abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/5\">",
"     5",
"    </a>",
"    ]. The sensitivity and specificity of diagnostic mammograms declined with breast density, younger age, and mammographic examination.",
"   </p>",
"   <p>",
"    Screening mammography is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H9#H9\">",
"     \"Screening for breast cancer\", section on 'Mammography'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     BI-RADS diagnostic categories",
"    </span>",
"    &nbsp;&mdash;&nbsp;The radiologist summarizes the mammographic findings using the American College of Radiology (ACR) BI-RADS (Breast Imaging Reporting and Data System) final diagnostic assessment categories, which indicate the relative likelihood of a normal, benign, or malignant diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The BI-RADS final assessment categories standardize both the reporting of mammographic findings and the recommendations for further management (ie, routine screening, short interval follow-up, or biopsy). Assessments are either incomplete (category 0) or final assessment categories (categories 1 through 6) as described on the table (",
"    <a class=\"graphic graphic_table graphicRef66601 \" href=\"UTD.htm?38/19/39227\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a mammogram is assigned category 0, additional evaluation is required for further characterization which may include additional mammographic views and or ultrasound, and rarely, magnetic resonance imaging (MRI). A BI-RADS designation of 4c or 5 should alert the pathologist that a malignant diagnosis is strongly suspected and that further evaluation of the specimen (and possible rebiopsy) is needed if the biopsy is initially interpreted as benign. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H15#H15\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'The BI-RADS categories'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Mammographic features of breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two general categories of mammographic findings suggestive of a breast cancer: soft tissue masses and clustered microcalcifications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Soft tissue mass/architectural distortion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most specific mammographic feature of malignancy is a spiculated soft tissue mass; nearly 90 percent of these lesions represent invasive cancer (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57593 \" href=\"UTD.htm?35/59/36799\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Approximately one-third of noncalcified cancers appear as spiculated masses, 25 percent as irregularly outlined masses, 25 percent as less specific round, oval or lobulated masses, less than 10 percent as well-defined round, oval, or lobulated masses, and 5 percent as areas of architectural distortion of dense tissue without an obvious mass [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The positive predictive value for malignancy of well-defined solid masses identified by ultrasound with benign imaging features is between 0 and 7 percent, and biopsy or short-term (three to six months) follow-up is considered appropriate management [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clustered microcalcifications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clustered microcalcifications are calcium particles of various size and shape measuring between 0.1 to 1 mm in diameter and numbering more than four to five per cubic centimeter. Microcalcifications are seen in approximately 60 percent of cancers detected mammographically (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75424 graphicRef66876 \" href=\"UTD.htm?41/51/42802\">",
"     image 3A-B",
"    </a>",
"    ). Histologically, these represent intraductal calcifications in areas of necrotic tumor (",
"    <a class=\"graphic graphic_picture graphicRef77048 \" href=\"UTD.htm?12/0/12292\">",
"     picture 1",
"    </a>",
"    ) or calcifications within mucin-secreting tumors such as the cribriform or micropapillary subtype of intraductal cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Linear branching microcalcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75424 graphicRef66876 \" href=\"UTD.htm?41/51/42802\">",
"     image 3A-B",
"    </a>",
"    ), most commonly associated with the comedo histologic subtype, have a higher predictive value for malignancy than do granular (ie, nonlinear irregular calcifications of varying size and shape) microcalcifications, particularly for high grade DCIS. However, breast cancers, including DCIS, more often present with the granular type of calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/8\">",
"     8",
"    </a>",
"    ]. Calcifications that are not suspicious for malignancy and considered benign include vascular and skin calcifications, rim-like calcifications, large coarse calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65088 \" href=\"UTD.htm?35/33/36368\">",
"     image 4",
"    </a>",
"    ), and smooth round or oval calcifications (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52281 \" href=\"UTD.htm?41/6/42094\">",
"     image 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Despite the association of microcalcifications with ductal carcinoma in situ (DCIS), mammographic appearance alone cannot differentiate between purely intraductal and invasive ductal breast cancers; there is no mammographic correlate of basement membrane invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/13\">",
"     13",
"    </a>",
"    ]. One-third of invasive carcinomas are associated with microcalcifications, with or without a soft tissue mass, and 10 percent of intraductal cancers present as a soft tissue mass without microcalcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link&amp;anchor=H100033227#H100033227\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\", section on 'Mammography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, mammographic findings such as masses and calcifications can be stratified by suspicion for malignancy, and the BI-RADS 4a, 4b, and 4c categories are helpful in alerting the referring physicians, the pathologists, and surgeons to the underlying risk of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/14\">",
"     14",
"    </a>",
"    ]. Low risk calcifications are much more likely to be benign (",
"    <a class=\"graphic graphic_table graphicRef66601 \" href=\"UTD.htm?38/19/39227\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'BI-RADS diagnostic categories'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Assessing the extent of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mammographic assessment of the extent of DCIS and early invasive carcinoma begins during diagnostic mammography and continues through the biopsy, specimen management, and the postexcision mammogram [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/8\">",
"     8",
"    </a>",
"    ]. Mammography of both breasts is particularly important in the patient with DCIS or invasive cancer who is considering breast conservation. Preoperative diagnostic mammography can help to define the extent of disease and may identify multifocal or multicentric cancer that could preclude breast conservation or signal a potential difficulty in achieving clear surgical margins. Multifocal disease is usually defined as involvement of several areas within a breast quadrant, probably representing disease along an entire duct. In contrast, multicentric disease involves multiple areas within different quadrants, probably representing involvement of multiple ducts.",
"   </p>",
"   <p>",
"    Although the extent of mammographic nonlinear branching microcalcifications frequently underestimates the pathologic extent of the malignancy, the discrepancy is less than 2 cm in 80 to 85 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/15\">",
"     15",
"    </a>",
"    ]. Several clusters of microcalcifications separated by normal appearing tissue should not be interpreted as multifocal or multicentric disease. Often, these represent areas of contiguous tumor that is only partially calcified within a ductal-lobule [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of a mass and associated calcifications often indicates the presence of an extensive intraductal component (EIC). EIC is defined pathologically as DCIS found adjacent to an invasive carcinoma, accounting for more than 25 percent of the volume of disease. This finding can be a predictor for more widespread residual tumor (usually DCIS) following gross excision of the lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H25#H25\">",
"     \"Breast conserving therapy\", section on 'Extensive intraductal component (EIC)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postoperative mammograms to look for residual calcifications after surgical resection should be considered when the microcalcifications are not clearly or completely documented on the specimen radiograph or when margins are close or positive [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. If a re-excision is to be recommended on the basis of residual calcifications, care should be taken to ensure that the calcifications are associated with malignancy on histopathology and not benign tissue. Multifocal disease is not necessarily a contraindication to breast conservation, but is one of the factors that should be taken into consideration along with breast size relative to the extent of disease on imaging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant limitation of mammographic assessment of disease extent is the obscuring of the borders or extent of the primary tumor by dense overlying tissue. Dense breasts can limit the sensitivity of mammography both for detection of breast cancers and for delineating disease extent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In this setting, contrast-enhanced breast magnetic resonance imaging (MRI) may complement mammographic staging. If the clinical extent of disease is larger than what can be appreciated by mammography, MRI may be considered. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Breast MRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mammographic assessment of tumor size for the staging of multifocal disease presents a unique dilemma. Most staging classifications require that the largest tumor mass be utilized for T staging, even in cases where multifocal disease is suspected. However, others suggest that the total surface area, volume, or aggregate measurements are a better indicator of prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Accurate delineation of the extent of odd-shaped, irregular, or multifocal tumors is important for treatment planning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For invasive cancers that are contiguous to the chest wall and not completely included on mammographic projections, ancillary imaging techniques such as MRI may be necessary to assess posterior tumor extension and pectoralis fascia or muscle involvement if that will determine a change in surgical approach or the use of neoadjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Assessment of ipsilateral disease with breast MRI'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Significance of intramammary lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramammary lymph nodes are detected in 1 to 28 percent of patients with breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/27-31\">",
"     27-31",
"    </a>",
"    ]. Benign nodes can often be distinguished from metastatic or infiltrated intramammary lymph nodes by their mammographic or sonographic appearance, but definitive assessment often requires histopathologic study [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/32\">",
"     32",
"    </a>",
"    ]. The presence of intramammary lymph node metastases appears to confer a worse prognosis, both in women who otherwise have stage I breast cancer based upon tumor size and axillary nodal status and in those with stage II disease [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/27\">",
"     27",
"    </a>",
"    ]. Isolated intramammary lymph node metastases are considered to represent stage II disease, even if the axillary nodes are uninvolved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ULTRASONOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound can be used to differentiate between solid and cystic breast masses that are palpable or detected mammographically. In addition, ultrasound evaluation of the axilla can be used to detect lymph nodes that are suspicious for axillary metastases. Ultrasound provides guidance for interventional procedures of suspicious areas in the breast or axilla.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H667081\">",
"    <span class=\"h2\">",
"     Breast ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound (US) examination of the breast is an important diagnostic adjunct to mammography. In patients suspected of having a breast cancer, breast US is most useful in the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      To further characterize a mammographically detected mass or an area of architectural distortion. Breast US can help to characterize solid masses as either benign or malignant. In one report, the sensitivity of US for malignancy was 98.4 percent, and the negative predictive value 99.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/33\">",
"       33",
"      </a>",
"      ]. Similar results have been reported in other studies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/12,34,35\">",
"       12,34,35",
"      </a>",
"      ]. Similar findings have been noted in subsequent studies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/12\">",
"       12",
"      </a>",
"      ]. However, US is highly operator-dependent and significant variability in the ability of radiologists to characterize solid breast lesions by US has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. A benign solid appearance on US should",
"      <strong>",
"       not",
"      </strong>",
"      be used to avoid biopsy of a mammographically or clinically suspicious mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H29#H29\">",
"       \"Breast imaging: Mammography and ultrasonography\", section on 'Role of ultrasound'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To identify a cystic mass. Simple cysts need no further intervention because the risk of cancer is very low; one series found no malignancies in 223 cysts [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/39\">",
"       39",
"      </a>",
"      ]. Indeterminate cysts can be aspirated under US guidance. The presence of an intracystic mass should prompt a fine needle aspiration (FNA) or core biopsy of the mass. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link\">",
"       \"Breast cysts: Clinical manifestations, diagnosis, and management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To further characterize a lesion when a mass detected on clinical breast examination cannot be seen clearly on mammogram (often in women with dense breasts).",
"     </li>",
"     <li>",
"      To determine whether a mammographically suspicious lesion can be visualized and therefore sampled by US-guided biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"       \"Breast biopsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      To measure and clip a lesion prior to neoadjuvant chemotherapy. For patients who present with large or locally advanced tumors for which neoadjuvant (induction) chemotherapy is considered, careful anatomic localization is critical to ensure that the surgeon can localize the area of tumor after neoadjuvant therapy. Typically, the lesion is measured both clinically and ultrasonographically, and reported in terms of size, the \"o'clock\" location on the breast surface, and the distance of the lesion from the nipple. The use of radio-opaque clips placed at the time of biopsy to localize the primary tumor in case there is a complete clinical and radiographic response to induction therapy is discussed below. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H6#H6\">",
"       \"Breast biopsy\", section on 'Clip placement'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Breast US is often added to the initial diagnostic evaluation for women with a suspected breast cancer if there is a palpable mass or a density is seen on mammogram. The benefit of this approach was suggested in a series of 2020 patients (470 with a palpable mass) who underwent clinical exam, mammography, and breast US [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/34\">",
"     34",
"    </a>",
"    ]. The systematic addition of breast US detected eight additional malignancies, and correctly downgraded 332 cases of suspected malignancy to no suspected malignancy (predominantly cysts or fibroadenoma). Thus, the main benefit of breast US was improved specificity when used in a targeted manner. The sensitivity, specificity, positive and negative predictive values for clinical examination plus mammography plus US were 96.9, 94.8, 39.2, and 99.9 percent, while the corresponding values for clinical examination plus mammography were 91.5, 87, 19.7, and 99.7 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454176705\">",
"    <span class=\"h2\">",
"     Axillary ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with clinically suspicious lymph nodes, preoperative axillary US with fine needle aspiration or core biopsy of suspicious areas provides a means to identify patients who have positive nodes. This information may be used to guide future additional surgery, radiation, or systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\", section on 'Lymph nodes'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H4#H4\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'The role of ultrasound in sentinel node evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BREAST MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all invasive breast carcinomas enhance on gadolinium contrast-enhanced MRI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/40-54\">",
"     40-54",
"    </a>",
"    ]. The sensitivity of breast MRI for breast carcinomas is between 88 and 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/48,55-57\">",
"     48,55-57",
"    </a>",
"    ]. However, a major disadvantage is the limited specificity of MRI due to enhancement of benign breast lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/40,42,44-48,58-65\">",
"     40,42,44-48,58-65",
"    </a>",
"    ]. In a meta-analysis of 44 studies evaluating diagnostic breast MRI in patients with breast lesions, pooled specificity was 72 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/66\">",
"     66",
"    </a>",
"    ]. Specificity can be improved, to some extent, by alterations in technique. The technique of breast MRI is discussed elsewhere. However, even using optimal technique, specificity is still insufficient to obviate the need for biopsy confirmation of an MRI abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=see_link\">",
"     \"MRI of the breast and emerging technologies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Assessment of ipsilateral disease with breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI is more sensitive than mammography, ultrasound, or physical examination and identifies additional ipsilateral disease in about 16 percent of women with a known breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/13,36,45,49,55,67-71\">",
"     13,36,45,49,55,67-71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because MRI is so sensitive, it was assumed that preoperative MRI would estimate the extent of disease more accurately than conventional imaging, thereby improving surgical planning (eg, prompting a change to mastectomy when breast conserving therapy had been previously considered [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/72\">",
"     72",
"    </a>",
"    ]) and enabling surgeons to better obtain clean margins in breast conserving surgery.",
"   </p>",
"   <p>",
"    However, available data has shown that preoperative breast MRI has not improved outcomes, overestimates the extent of disease, and has overall limited value [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/73-84\">",
"     73-84",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It was already known from postmastectomy pathology studies that additional sites of tumor are frequently present in the ipsilateral breast [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/73\">",
"       73",
"      </a>",
"      ]. In fact, the entire purpose of RT in women undergoing breast conserving surgery is to eradicate sites of clinically occult disease in the ipsilateral breast. Multiple prospective randomized trials of breast conserving surgery with and without RT have demonstrated that the high risk of in-breast recurrence (40 percent) without RT is reduced to &lt;10 percent with RT [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/74-79\">",
"       74-79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is no evidence that routine use of breast MRI results in fewer positive margins at the time of partial mastectomy or a lower rate of reoperation to achieve clear margins [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/72,80\">",
"       72,80",
"      </a>",
"      ]. A United Kingdom (UK) randomized trial (COMICE) evaluating the role of breast MRI in 1623 women with newly diagnosed breast cancer showed no difference in the reoperation rate with or without the use of preoperative MRI (18.7 and 19.3 percent respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/80,81\">",
"       80,81",
"      </a>",
"      ]. The lack of a difference in reoperation rates could reflect the UK&rsquo;s low reported re-excision rate of 10 percent in contrast to US institutions where the rates are closer to 25 percent, presumably due to attempts at removing the smallest volume of tissue possible for breast conservation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/82\">",
"       82",
"      </a>",
"      ]. In addition, many women had mastectomies (27.6 percent in the group randomized to MRI) without pathological verification of disease as not all centers in this trial performed MRI biopsy or localization.",
"     </li>",
"     <li>",
"      Because of its low specificity, MRI can delay treatment by necessitating additional biopsies [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/36,72\">",
"       36,72",
"      </a>",
"      ]. In one study, MRI was associated with a significant 22-day delay in definitive treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a review of 1558 consecutive patients with invasive breast cancer",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      noninvasive breast cancer, MRI was not associated with an advantage to lower re-excision rate, improve the rate of breast conservation surgery achievement, or lower recurrence rate [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Assessment of contralateral disease with breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;MRI imaging of the contralateral breast identifies a suspicious, clinically occult finding in 9 to 12 percent of women with a unilateral breast cancer, but cannot distinguish between benign and malignant lesions. In general, a synchronous clinically and mammographically inapparent malignancy will be found in 3 to 5 percent of cases, approximately one-half of which are invasive cancer, and the remainder, intraductal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/35,50,85-94\">",
"     35,50,85-94",
"    </a>",
"    ], and results in about a 12 percent chance of biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/35,50,85-92,95\">",
"     35,50,85-92,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a meta-analysis of 22 studies (3253 women) of women with newly diagnosed breast cancer, the pooled estimate for detecting a suspicious abnormality that was occult on conventional imaging was 9.3 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/86\">",
"     86",
"    </a>",
"    ]. The incremental cancer detection rate with MRI was only 4 percent because more than half of the suspicious abnormalities detected by MRI alone proved to be benign. The summary estimate of positive predictive value was 48 percent. Interestingly, 10 women underwent contralateral mastectomy based upon MRI findings without a preoperative biopsy. Of these, only three had malignancy and the remaining seven were benign. Of the 42 women who underwent prophylactic mastectomy despite a negative MRI, five (12 percent) unexpected malignancies were identified on final pathology.",
"   </p>",
"   <p>",
"    The clinical significance, especially the survival benefit, of detecting these cancers has not been addressed. As is the case with MRI of the affected breast, the finding of a contralateral malignancy on breast MRI may lead to overtreatment. Many of these subclinical cancers are effectively treated with the systemic therapy used for the treatment of the initial cancer. As an example, in the Early Breast Cancer Trialists Collaborative Group (EBCTCG) overview analysis, the incidence of contralateral breast cancer was reduced by 50 percent in patients receiving five years of adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , and by 20 percent in patients receiving adjuvant chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Finally, the detection of these contralateral cancers must be weighed against the added time and additional costs associated with MRI and MRI-guided biopsy. Of MRI-detected lesions recommended for biopsy, only about one in five prove to be malignant [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/97\">",
"     97",
"    </a>",
"    ]. The available data do not show that detection rates or clinical utility differs in any subset of breast pattern (including dense breasts) or histologic type (DCIS, ductal or lobular carcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/15,32,34,36,98\">",
"     15,32,34,36,98",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link&amp;anchor=H100033269#H100033269\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\", section on 'Role of magnetic resonance imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For all of these reasons, the role of MRI to assess the contralateral breast is controversial and cannot be routinely recommended for the majority of women with a newly diagnosed breast cancer.",
"   </p>",
"   <p>",
"    There are some clinical scenarios where breast MRI might be considered prior to therapy to assess contralateral disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365150103\">",
"    <span class=\"h3\">",
"     High risk women",
"    </span>",
"    &nbsp;&mdash;&nbsp;A contralateral breast MRI is reasonable for women with newly diagnosed breast cancer who are considered at very high risk for contralateral breast cancer based on the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is a known carrier of a breast cancer gene mutation in BRCA 1 or BRCA 2 (hereditary breast and ovarian cancer syndrome). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=see_link\">",
"       \"Genetic testing for hereditary breast and ovarian cancer syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient is a first-degree relative of a known BRCA 1 or BRCA 2 mutation carrier.",
"     </li>",
"     <li>",
"      The patient has an estimated lifetime risk of breast cancer of 20 percent or higher, as estimated using the BRCA-PRO model, used to identify women for breast cancer genetic testing [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/99\">",
"       99",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=see_link&amp;anchor=H13#H13\">",
"       \"Risk prediction models for breast cancer screening\", section on 'Clinical use of risk prediction models'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient was previously treated with radiation to the chest wall (eg, for Hodgkin lymphoma). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=see_link&amp;anchor=H25#H25\">",
"       \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Breast cancer'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient has a personal history or a first-degree relative with Li-Fraumeni syndrome or one of the PTEN hamartoma tumor syndromes such as Cowden syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link\">",
"       \"Characteristics of hereditary breast and ovarian cancer syndromes\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=see_link\">",
"       \"Li-Fraumeni syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"       \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365150280\">",
"    <span class=\"h3\">",
"     Issues related to breast reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons prefer a preoperative MRI to assess the opposite breast in a woman undergoing significant reconstructive procedures such as a partial mastectomy with contralateral breast reduction or mastectomy with flap reconstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An abdominal flap can only be raised once, and the reconstructive technique used might differ if bilateral reconstruction rather than unilateral reconstruction is planned. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=see_link&amp;anchor=H20#H20\">",
"       \"Breast reconstruction in women with breast cancer\", section on 'Autogenous tissue reconstruction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When a contralateral reduction is planned as part of the reconstructive process, MRI of the contralateral breast may avoid unexpected disease, particularly if there is a condition that will make mammographic screening less sensitive, such as dense breasts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365150166\">",
"    <span class=\"h2\">",
"     Effect of tumor histology on MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor histology does not appear to be a predictor for the utility of breast MRI. Although some studies have reported that MRI accurately determines disease extent for invasive lobular cancers, which are often associated with only subtle mammographic changes, this is not uniformly the case [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/15,32,34,36,98\">",
"     15,32,34,36,98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although early studies reported difficulty in detecting ductal carcinomas in situ (DCIS) on MRI, subsequent studies suggest that MRI can accurately determine the extent of high grade DCIS, with sensitivities of 89 to 94 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/36,50,100\">",
"     36,50,100",
"    </a>",
"    ]. MRI detection of DCIS has been shown to improve with experience [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Effect of MRI on mastectomy rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have reported that MRI results in changes in surgical management and may be a factor in the increased use of mastectomy and bilateral mastectomy in women with newly diagnosed breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/36,50-52,69,94,102,103\">",
"     36,50-52,69,94,102,103",
"    </a>",
"    ]. As an example, in a population of 3606 women with newly diagnosed breast cancer, women who underwent MRI were twice as likely to have contralateral prophylactic mastectomy performed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Effect of MRI on recurrence and survival rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unresolved question is whether the routine use of MRI to detect multifocal or multicentric disease results in fewer local recurrences and better long-term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In a retrospective review of 756 patients treated for newly diagnosed breast cancer, 215 patients had breast MRI as part of their initial evaluation, and 541 did not [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/104\">",
"     104",
"    </a>",
"    ]. The eight-year rates of any local failure or local-only first failure were 3 and 4 percent with and without MRI, respectively, and rates were similar in women who had invasive or intraductal cancers. Furthermore, there were also no differences in eight-year rates of overall or cause-specific survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Guidelines for the use of preoperative breast MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of breast MRI in the preoperative evaluation of a newly diagnosed breast cancer has increased significantly over the last ten years, largely due to the high sensitivity for detecting otherwise occult breast cancer in the affected and contralateral breasts. Advocates of MRI cite as potential benefits an improvement in the selection of patients for breast conserving surgery, a decrease in the number of surgical procedures needed to obtain clear margins, and the synchronous detection of contralateral cancers. However, there are no data from prospective randomized trials that demonstrate improved outcomes from the addition of breast MRI to the diagnostic evaluation of newly diagnosed breast cancer. Furthermore, because of limited specificity, the use of breast MRI increases unnecessary surgery, delays definitive treatment, and may lead to overtreatment.",
"   </p>",
"   <p>",
"    Routine preoperative MRI is not indicated for the majority of patients with early stage breast cancer. In keeping with consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) and the available data, we and others consider the role of breast MRI in the evaluation of women with newly diagnosed breast cancer as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/20,83,93,97,105-107\">",
"     20,83,93,97,105-107",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evaluation of a woman with a newly diagnosed breast cancer in whom the clinical extent of disease is larger than what is appreciated by mammography (particularly in the setting of dense breasts which lower the sensitivity of mammography). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Assessing the extent of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For invasive cancers that are contiguous to the chest wall and not completely included on mammographic projections, MRI may be necessary to assess posterior tumor extension and pectoralis fascia or muscle involvement if that will determine a change in surgical approach or the use of neoadjuvant therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Assessing the extent of disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with axillary nodal metastases and a clinically occult primary tumor, breast MRI can facilitate the identification of occult breast cancer and help select patients most likely to benefit from surgery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=see_link&amp;anchor=H8#H8\">",
"       \"Axillary node metastases with occult primary breast cancer\", section on 'Breast MRI'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with Paget&rsquo;s disease of the breast who have a negative physical examination and mammogram, breast MRI can define the extent of disease and aid in treatment planning [",
"      <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/108,109\">",
"       108,109",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link&amp;anchor=H9#H9\">",
"       \"Paget disease of the breast\", section on 'Magnetic resonance imaging'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In women with locally advanced breast cancer who are being considered for upfront (neoadjuvant) systemic therapy, breast MRI may be used to define the extent of disease, and potential for breast conserving therapy. However, following neoadjuvant therapy, breast MRI can overestimate residual invasive cancer, and is not accurate for predicting pathologic response. Methods for monitoring the response to neoadjuvant systemic therapy in locally advanced breast cancer are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1529?source=see_link&amp;anchor=H1192123#H1192123\">",
"       \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Treatment evaluation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with very high risk for contralateral disease (for example, because of an inherited predisposing condition, or prior chest wall irradiation). (See",
"      <a class=\"local\" href=\"#H365150103\">",
"       'High risk women'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are planning extensive reconstructive surgery, breast MRI may be used to identify occult contralateral cancers. (See",
"      <a class=\"local\" href=\"#H365150280\">",
"       'Issues related to breast reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women should be informed of the risks and benefits of preoperative breast MRI. The limits of the accuracy of MRI should be discussed with patients, so that they understand the need for biopsy of MRI detected lesions before definitive surgery. Breast MRI should be performed with a dedicated breast coil by expert breast imaging radiologists in institutions that have the capability to perform MRI guided needle biopsy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wire localization of the findings.",
"     </li>",
"     <li>",
"      Surgical decisions should",
"      <strong>",
"       not",
"      </strong>",
"      be based on MRI findings alone. MRI findings alone should not be used to change surgical planning and conversion from breast conservation to mastectomy. All suspicious findings on",
"      <strong>",
"      </strong>",
"      MRI require pathologic confirmation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ALGORITHMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is significant variability in the diagnostic evaluation of women with suspected breast cancer. Patterns of referral vary dramatically, as do rates of screening mammography recall. The work-up and evaluation may differ, depending upon which clinician is seen first. Diagnostic algorithms are helpful as general guidelines, but they must be adapted to include patient preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mammographic abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The figure (",
"    <a class=\"graphic graphic_algorithm graphicRef65978 \" href=\"UTD.htm?3/17/3344\">",
"     algorithm 1",
"    </a>",
"    ) describes an algorithmic approach to the evaluation of a mammographic abnormality, which integrates BI-RADS assessment categories (",
"    <a class=\"graphic graphic_table graphicRef66601 \" href=\"UTD.htm?38/19/39227\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Women with palpable masses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Algorithms for clinical and imaging evaluation of palpable masses are stratified by the age of the woman. Even in the setting of palpable masses, image guidance may improve diagnostic accuracy. A clinically suspicious mass should be biopsied regardless of imaging findings, as 10 to 15 percent of such lesions can be mammographically occult [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Younger women",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic approach to the evaluation of palpable masses in younger women differs among experts.",
"   </p>",
"   <p>",
"    The approach that is advocated by the National Comprehensive Cancer Network (NCCN) is an initial breast US (",
"    <a class=\"graphic graphic_algorithm graphicRef54674 \" href=\"UTD.htm?31/37/32337\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80301 \" href=\"UTD.htm?8/11/8383\">",
"     algorithm 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/20\">",
"     20",
"    </a>",
"    ]. If the examination is indeterminate or suspicious, mammography is often performed, although its utility in young women with breast masses or nodularity is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/110\">",
"     110",
"    </a>",
"    ], and a biopsy is probably warranted even if the mammogram is negative. If the mass cannot be visualized by US, mammography may be considered, or alternatively, a tissue biopsy or period of observation may be appropriate depending upon the level of clinical suspicion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternatively, aspiration can be selected as an initial approach to a breast mass in a younger woman (",
"    <a class=\"graphic graphic_algorithm graphicRef54674 \" href=\"UTD.htm?31/37/32337\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/20\">",
"     20",
"    </a>",
"    ]. If no fluid is aspirated and cytologic review of cell blocks from the needle washings are nondiagnostic, then US is performed. If the capacity to perform or interpret FNA is limited at an institution, this approach is not optimal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the initial evaluation shows cancer, bilateral breast imaging should be performed promptly and prior to any definitive surgery to exclude unsuspected or more extensive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a palpable mass or mass is appreciated, bilateral diagnostic mammography should be performed prior to biopsy, even if the mass is clinically suspicious for cancer (",
"    <a class=\"graphic graphic_algorithm graphicRef80301 \" href=\"UTD.htm?8/11/8383\">",
"     algorithm 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef74666 \" href=\"UTD.htm?10/12/10435\">",
"     algorithm 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/20\">",
"     20",
"    </a>",
"    ]. Fine needle aspiration or core needle biopsy may alter both mammographic or US appearance. The goal of imaging in this setting is not to establish a diagnosis of cancer, but rather to identify other suspicious areas or calcifications in either breast that might impact treatment. This evaluation should be performed prior to percutaneous biopsy, so that biopsy of additional suspicious lesions can be undertaken at one time. If the lesion is large and breast conservation is not an option, this is less important. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H969399129\">",
"    <span class=\"h1\">",
"     BIOPSY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the patient with a suspicious mammographic abnormality or palpable breast mass, the obligatory diagnostic technique is biopsy. Surgical biopsy should not be utilized as a diagnostic tool unless percutaneous palpation-guided or image-guided biopsy is not feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?23/36/24138/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. A preoperative histologic diagnosis of invasive carcinoma may allow the surgeon to plan a single operation to treat the cancer, including sentinel lymph node biopsy or full axillary dissection, depending upon the clinical circumstances. Excision of more extensive areas of DCIS may also be optimally planned if the diagnosis has been established by percutaneous core needle biopsy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link\">",
"     \"Breast biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that a needle biopsy may cause hematoma and inflammation at the site of the mass and enlargement of the axillary nodes, which can make clinical assessment and surgical planning more difficult. Physical exam changes from needle biopsy often resolve by the time of surgery. If the palpable lesion is small or subtle, it is helpful to arrange wire localization of the clip placed at the time of biopsy to facilitate breast conserving surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of breast cancers are diagnosed as a result of an abnormal mammogram, but the majority of mammographic findings represent benign tissue. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinically suspicious mass should be biopsied, regardless of imaging findings, as 10 to 15 percent of such lesions can be mammographically occult. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who have an abnormal screening mammogram need further diagnostic evaluation with magnification views, spot compression views",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      targeted ultrasonography to determine the need for tissue sampling or biopsy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The American College of Radiology (ACR) BI-RADS (Breast Imaging Reporting and Data System) final diagnostic assessment categories indicate the relative likelihood of a normal, benign, or malignant diagnosis and standardize both the reporting of mammographic findings and the recommendations for further management. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'BI-RADS diagnostic categories'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While intervention is recommended for all BI-RADS category 4 lesions, the probability of malignancy can be stratified as low, intermediate and moderate to high in subclassifications of BI-RADS 4 as 4a, b, or c. The use of these subclassifications provides a useful estimate of the risk that a suspicious lesion will prove to be malignant.",
"     </li>",
"     <li>",
"      Ultrasound (US) examination of the breast is an important diagnostic adjunct to mammography and is used to differentiate between solid and cystic masses and to provide guidance for interventional procedures. (See",
"      <a class=\"local\" href=\"#H667081\">",
"       'Breast ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast MRI is highly sensitive, and can identify foci of cancer that are not evident on physical examination, mammogram, or ultrasound. Although advocates of MRI cite as potential benefits improved selection of patients for breast conserving surgery, a decrease in the number of surgical procedures needed to obtain clear margins, and the synchronous detection of contralateral cancers, there are no data from prospective randomized trials that demonstrate improved outcomes from the addition of breast MRI to the diagnostic evaluation of newly diagnosed breast cancer. Furthermore, because of limited specificity, the use of breast MRI increases the number of unnecessary biopsies, delays definitive treatment, and increases the number of patients undergoing mastectomy. As a result, breast MRI is not recommended as a routine component of the diagnostic evaluation of breast cancer for most women. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Breast MRI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We and others consider the role of breast MRI in the evaluation of women with newly diagnosed breast cancer in the following circumstances. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Guidelines for the use of preoperative breast MRI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with axillary nodal metastases and a clinically occult primary tumor.",
"     </li>",
"     <li>",
"      When the clinical extent of disease is larger than what is appreciated by mammography (particularly in the setting of dense breasts which lower the sensitivity of mammography).",
"     </li>",
"     <li>",
"      To assess posterior tumor extension and pectoralis fascia or muscle involvement if that will determine a change in surgical approach or the use of neoadjuvant therapy.",
"     </li>",
"     <li>",
"      For women with Paget&rsquo;s disease of the breast who have a negative physical examination and mammogram.",
"     </li>",
"     <li>",
"      In women with locally advanced breast cancer who are being considered for upfront (neoadjuvant) systemic therapy.",
"     </li>",
"     <li>",
"      For women with very high risk for contralateral disease (for example, because of an inherited predisposing condition, or prior chest wall irradiation) or those who are undergoing a prophylactic contralateral mastectomy.",
"     </li>",
"     <li>",
"      For women who are planning extensive reconstructive surgery (eg, rectus abdominus myocutaneous flap), breast MRI may be used to identify occult contralateral cancers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Suspicious lesions seen on MRI",
"      <strong>",
"       must",
"      </strong>",
"      be biopsied to confirm diagnosis before planning definitive surgery. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Breast MRI'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic algorithms can provide useful guidelines for the work up of a suspicious finding on breast imaging or breast examination. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnostic algorithms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the patient with a suspicious mammographic abnormality or palpable breast mass, the obligatory diagnostic technique is biopsy. Surgical biopsy should not be utilized as a diagnostic tool unless percutaneous palpation-guided or image-guided biopsy is not feasible. (See",
"      <a class=\"local\" href=\"#H969399129\">",
"       'Biopsy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/1\">",
"      Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/2\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/3\">",
"      Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/4\">",
"      Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353:1784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/5\">",
"      Barlow WE, Lehman CD, Zheng Y, et al. Performance of diagnostic mammography for women with signs or symptoms of breast cancer. J Natl Cancer Inst 2002; 94:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/6\">",
"      Chang JH, Vines E, Bertsch H, et al. The impact of a multidisciplinary breast cancer center on recommendations for patient management: the University of Pennsylvania experience. Cancer 2001; 91:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/7\">",
"      Smart CR, Hartmann WH, Beahrs OH, Garfinkel L. Insights into breast cancer screening of younger women. Evidence from the 14-year follow-up of the Breast Cancer Detection Demonstration Project. Cancer 1993; 72:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/8\">",
"      Stomper PC, Winston PS, Proulx GM, et al. Mammographic detection and staging of ductal carcinoma in situ: mammographic-pathologic correlation. Semin Breast Dis 2000; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/9\">",
"      Lin C, Moore D, DeMichele A, et al. Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening (abstract 1503). (Abstract available online at www.abstract.asco.org/AbstView_65_31279.html, accessed February 11, 2010). J Clin Oncol 2009; 27:1503s.",
"     </a>",
"    </li>",
"    <li>",
"     Breast Imaging Reporting and Data System (BI-RADS) Atlas, 4th ed, American College of Radiology, Reston, VA 2003.",
"    </li>",
"    <li>",
"     Stomper PC. Breast imaging. In: Atlas of Breast Cancer, Hayes DF (Ed), Mosby, Philadelphia 2000. p.54.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/12\">",
"      Harvey JA, Nicholson BT, Lorusso AP, et al. Short-term follow-up of palpable breast lesions with benign imaging features: evaluation of 375 lesions in 320 women. AJR Am J Roentgenol 2009; 193:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/13\">",
"      Stomper PC, Geradts J, Edge SB, Levine EG. Mammographic predictors of the presence and size of invasive carcinomas associated with malignant microcalcification lesions without a mass. AJR Am J Roentgenol 2003; 181:1679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/14\">",
"      Sanders MA, Roland L, Sahoo S. Clinical implications of subcategorizing BI-RADS 4 breast lesions associated with microcalcification: a radiology-pathology correlation study. Breast J 2010; 16:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/15\">",
"      Holland R, Hendriks JH, Vebeek AL, et al. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet 1990; 335:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/16\">",
"      Kopans DB, Lindfors K, McCarthy KA, Meyer JE. Spring hookwire breast lesion localizer: use with rigid-compression mammographic systems. Radiology 1985; 157:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/17\">",
"      Healey EA, Osteen RT, Schnitt SJ, et al. Can the clinical and mammographic findings at presentation predict the presence of an extensive intraductal component in early stage breast cancer? Int J Radiat Oncol Biol Phys 1989; 17:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/18\">",
"      Gluck BS, Dershaw DD, Liberman L, Deutch BM. Microcalcifications on postoperative mammograms as an indicator of adequacy of tumor excision. Radiology 1993; 188:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/19\">",
"      Waddell BE, Stomper PC, DeFazio JL, et al. Postexcision mammography is indicated after resection of ductal carcinoma-in-situ of the breast. Ann Surg Oncol 2000; 7:665.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/21\">",
"      Baines CJ, Dayan R. A tangled web: factors likely to affect the efficacy of screening mammography. J Natl Cancer Inst 1999; 91:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/22\">",
"      Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000; 92:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/23\">",
"      Fish EB, Chapman JA, Link MA. Assessment of tumor size for multifocal primary breast cancer. Ann Surg Oncol 1998; 5:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/24\">",
"      Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol 2005; 23:7497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/25\">",
"      Andea AA, Wallis T, Newman LA, et al. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 2002; 94:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/26\">",
"      Morris EA, Schwartz LH, Drotman MB, et al. Evaluation of pectoralis major muscle in patients with posterior breast tumors on breast MR images: early experience. Radiology 2000; 214:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/27\">",
"      Shen J, Hunt KK, Mirza NQ, et al. Intramammary lymph node metastases are an independent predictor of poor outcome in patients with breast carcinoma. Cancer 2004; 101:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/28\">",
"      Egan RL, McSweeney MB. Intramammary lymph nodes. Cancer 1983; 51:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/29\">",
"      Jadusingh IH. Intramammary lymph nodes. J Clin Pathol 1992; 45:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/30\">",
"      Stomper PC, Leibowich S, Meyer JE. The prevalence and distribution of well circumscribed nodules on screening mammography: Analysis of 1500 mammograms. Breast Dis 1991; 4:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/31\">",
"      Upponi S, Kalra S, Poultsidis A, et al. The significance of intramammary nodes in primary breast cancer. Eur J Surg Oncol 2001; 27:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/32\">",
"      G&uuml;nhan-Bilgen I, Memi A, Ust&uuml;n EE. Metastatic intramammary lymph nodes: mammographic and ultrasonographic features. Eur J Radiol 2001; 40:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/33\">",
"      Stavros AT, Thickman D, Rapp CL, et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/34\">",
"      Flobbe K, Bosch AM, Kessels AG, et al. The additional diagnostic value of ultrasonography in the diagnosis of breast cancer. Arch Intern Med 2003; 163:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/35\">",
"      Soo MS, Rosen EL, Baker JA, et al. Negative predictive value of sonography with mammography in patients with palpable breast lesions. AJR Am J Roentgenol 2001; 177:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/36\">",
"      Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004; 233:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/37\">",
"      Baker JA, Kornguth PJ, Soo MS, et al. Sonography of solid breast lesions: observer variability of lesion description and assessment. AJR Am J Roentgenol 1999; 172:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/38\">",
"      Rahbar G, Sie AC, Hansen GC, et al. Benign versus malignant solid breast masses: US differentiation. Radiology 1999; 213:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/39\">",
"      Sickles EA, Filly RA, Callen PW. Benign breast lesions: ultrasound detection and diagnosis. Radiology 1984; 151:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/40\">",
"      Kaiser WA, Zeitler E. MR imaging of the breast: fast imaging sequences with and without Gd-DTPA. Preliminary observations. Radiology 1989; 170:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/41\">",
"      Revel D, Brasch RC, Paajanen H, et al. Gd-DTPA contrast enhancement and tissue differentiation in MR imaging of experimental breast carcinoma. Radiology 1986; 158:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/42\">",
"      Heywang SH, Hahn D, Schmidt H, et al. MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/43\">",
"      Heywang SH, Wolf A, Pruss E, et al. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/44\">",
"      Stack JP, Redmond OM, Codd MB, et al. Breast disease: tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990; 174:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/45\">",
"      Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/46\">",
"      Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. Radiology 1994; 190:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/47\">",
"      Pierce WB, Harms SE, Flamig DP, et al. Three-dimensional gadolinium-enhanced MR imaging of the breast: pulse sequence with fat suppression and magnetization transfer contrast. Work in progress. Radiology 1991; 181:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/48\">",
"      Bluemke DA, Gatsonis CA, Chen MH, et al. Magnetic resonance imaging of the breast prior to biopsy. JAMA 2004; 292:2735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/49\">",
"      Liberman L, Morris EA, Dershaw DD, et al. MR imaging of the ipsilateral breast in women with percutaneously proven breast cancer. AJR Am J Roentgenol 2003; 180:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/50\">",
"      DeMartini W, Lehman C. A review of current evidence-based clinical applications for breast magnetic resonance imaging. Top Magn Reson Imaging 2008; 19:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/51\">",
"      Schelfout K, Van Goethem M, Kersschot E, et al. Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004; 30:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/52\">",
"      Fischer U, Kopka L, Grabbe E. Breast carcinoma: effect of preoperative contrast-enhanced MR imaging on the therapeutic approach. Radiology 1999; 213:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/53\">",
"      Mumtaz H, Hall-Craggs MA, Davidson T, et al. Staging of symptomatic primary breast cancer with MR imaging. AJR Am J Roentgenol 1997; 169:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/54\">",
"      Schnall MD, Blume J, Bluemke DA, et al. MRI detection of distinct incidental cancer in women with primary breast cancer studied in IBMC 6883. J Surg Oncol 2005; 92:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/55\">",
"      Esserman L, Hylton N, Yassa L, et al. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 1999; 17:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/56\">",
"      Esserman L, Hylton N, George T, Weidner N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J 1999; 5:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/57\">",
"      Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol 2001; 8:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/58\">",
"      Gribbestad IS, Nilsen G, Fj&oslash;sne H, et al. Contrast-enhanced magnetic resonance imaging of the breast. Acta Oncol 1992; 31:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/59\">",
"      Flickinger FW, Allison JD, Sherry RM, Wright JC. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI. Magn Reson Imaging 1993; 11:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/60\">",
"      Dao TH, Rahmouni A, Campana F, et al. Tumor recurrence versus fibrosis in the irradiated breast: differentiation with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 187:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/61\">",
"      Gilles R, Guinebreti&egrave;re JM, Shapeero LG, et al. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: preliminary results in 26 patients. Radiology 1993; 188:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/62\">",
"      Heywang SH, Hilbertz T, Pruss E, et al. [Dynamic contrast medium studies with flash sequences in nuclear magnetic resonance tomography of the breast]. Digitale Bilddiagn 1988; 8:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/63\">",
"      Rubens D, Totterman S, Chacko AK, et al. Gadopentetate dimeglumine-enhanced chemical-shift MR imaging of the breast. AJR Am J Roentgenol 1991; 157:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/64\">",
"      Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced TurboFLASH subtraction technique. Radiology 1994; 193:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/65\">",
"      Hulka CA, Smith BL, Sgroi DC, et al. Benign and malignant breast lesions: differentiation with echo-planar MR imaging. Radiology 1995; 197:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/66\">",
"      Peters NH, Borel Rinkes IH, Zuithoff NP, et al. Meta-analysis of MR imaging in the diagnosis of breast lesions. Radiology 2008; 246:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/67\">",
"      Tillman GF, Orel SG, Schnall MD, et al. Effect of breast magnetic resonance imaging on the clinical management of women with early-stage breast carcinoma. J Clin Oncol 2002; 20:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/68\">",
"      Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer 2002; 9:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/69\">",
"      Bedrosian I, Mick R, Orel SG, et al. Changes in the surgical management of patients with breast carcinoma based on preoperative magnetic resonance imaging. Cancer 2003; 98:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/70\">",
"      Bilimoria KY, Cambic A, Hansen NM, Bethke KP. Evaluating the impact of preoperative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg 2007; 142:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/71\">",
"      Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008; 26:3248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/72\">",
"      Bleicher RJ, Ciocca RM, Egleston BL, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg 2009; 209:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/73\">",
"      Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 1985; 56:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/74\">",
"      Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002; 347:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/75\">",
"      Veronesi U, Saccozzi R, Del Vecchio M, et al. Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast. N Engl J Med 1981; 305:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/76\">",
"      Sarrazin D, L&ecirc; MG, Arriagada R, et al. Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989; 14:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/77\">",
"      van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000; 92:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/78\">",
"      Jacobson JA, Danforth DN, Cowan KH, et al. Ten-year results of a comparison of conservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995; 332:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/79\">",
"      Blichert-Toft M, Rose C, Andersen JA, et al. Danish randomized trial comparing breast conservation therapy with mastectomy: six years of life-table analysis. Danish Breast Cancer Cooperative Group. J Natl Cancer Inst Monogr 1992; :19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/80\">",
"      Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet 2010; 375:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/81\">",
"      Turnbull LW, Brown SR, Olivier C, et al. Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE). Health Technol Assess 2010; 14:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/82\">",
"      Morris EA. Should we dispense with preoperative breast MRI? Lancet 2010; 375:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/83\">",
"      Shin HC, Han W, Moon HG, et al. Limited value and utility of breast MRI in patients undergoing breast-conserving cancer surgery. Ann Surg Oncol 2012; 19:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/84\">",
"      Weber JJ, Bellin LS, Milbourn DE, et al. Selective preoperative magnetic resonance imaging in women with breast cancer: no reduction in the reoperation rate. Arch Surg 2012; 147:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/85\">",
"      Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007; 356:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/86\">",
"      Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol 2009; 27:5640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/87\">",
"      Sorbero ME, Dick AW, Beckjord EB, Ahrendt G. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 2009; 16:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/88\">",
"      Slanetz PJ, Edmister WB, Yeh ED, et al. Occult contralateral breast carcinoma incidentally detected by breast magnetic resonance imaging. Breast J 2002; 8:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/89\">",
"      Liberman L, Morris EA, Kim CM, et al. MR imaging findings in the contralateral breast of women with recently diagnosed breast cancer. AJR Am J Roentgenol 2003; 180:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/90\">",
"      Lee SG, Orel SG, Woo IJ, et al. MR imaging screening of the contralateral breast in patients with newly diagnosed breast cancer: preliminary results. Radiology 2003; 226:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/91\">",
"      Pediconi F, Catalano C, Roselli A, et al. Contrast-enhanced MR mammography for evaluation of the contralateral breast in patients with diagnosed unilateral breast cancer or high-risk lesions. Radiology 2007; 243:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/92\">",
"      Lehman CD, Blume JD, Thickman D, et al. Added cancer yield of MRI in screening the contralateral breast of women recently diagnosed with breast cancer: results from the International Breast Magnetic Resonance Consortium (IBMC) trial. J Surg Oncol 2005; 92:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/93\">",
"      Houssami N, Hayes DF. Review of preoperative magnetic resonance imaging (MRI) in breast cancer: should MRI be performed on all women with newly diagnosed, early stage breast cancer? CA Cancer J Clin 2009; 59:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/94\">",
"      Miller BT, Abbott AM, Tuttle TM. The influence of preoperative MRI on breast cancer treatment. Ann Surg Oncol 2012; 19:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/95\">",
"      Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23:7703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/96\">",
"      Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/97\">",
"      Orel S. Who should have breast magnetic resonance imaging evaluation? J Clin Oncol 2008; 26:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/98\">",
"      Yeh ED, Slanetz PJ, Edmister WB, et al. Invasive lobular carcinoma: spectrum of enhancement and morphology on magnetic resonance imaging. Breast J 2003; 9:13.",
"     </a>",
"    </li>",
"    <li>",
"     BRCAPRO available for downloading at www4.utsouthwestern.edu/breasthealth/cagene/ (Accessed on May 06, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/100\">",
"      Kim do Y, Moon WK, Cho N, et al. MRI of the breast for the detection and assessment of the size of ductal carcinoma in situ. Korean J Radiol 2007; 8:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/101\">",
"      Warner E, Causer PA, Wong JW, et al. Improvement in DCIS detection rates by MRI over time in a high-risk breast screening study. Breast J 2011; 17:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/102\">",
"      Katipamula R, Degnim AC, Hoskin T, et al. Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol 2009; 27:4082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/103\">",
"      Orel SG, Schnall MD, Powell CM, et al. Staging of suspected breast cancer: effect of MR imaging and MR-guided biopsy. Radiology 1995; 196:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/104\">",
"      Solin LJ, Orel SG, Hwang WT, et al. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008; 26:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/105\">",
"      Morrow M. Magnetic resonance imaging in the breast cancer patient: curb your enthusiasm. J Clin Oncol 2008; 26:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/106\">",
"      Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer 2008; 44:2742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/107\">",
"      Lehman CD, DeMartini W, Anderson BO, Edge SB. Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw 2009; 7:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/108\">",
"      Morrogh M, Morris EA, Liberman L, et al. MRI identifies otherwise occult disease in select patients with Paget disease of the nipple. J Am Coll Surg 2008; 206:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/109\">",
"      Frei KA, Bonel HM, Pelte MF, et al. Paget disease of the breast: findings at magnetic resonance imaging and histopathologic correlation. Invest Radiol 2005; 40:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/110\">",
"      Hindle WH, Davis L, Wright D. Clinical value of mammography for symptomatic women 35 years of age and younger. Am J Obstet Gynecol 1999; 180:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/111\">",
"      Stomper PC, Winston JS, Proulx GM, et al. Mammographic detection and staging of ductal carcinoma in situ: Mammographic-pathologic correlation. Semin Breast Dis 2000; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/36/24138/abstract/112\">",
"      Silverstein MJ, Recht A, Lagios MD, et al. Special report: Consensus conference III. Image-detected breast cancer: state-of-the-art diagnosis and treatment. J Am Coll Surg 2009; 209:504.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 808 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-85.214.214.87-D5DBC4741A-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24138=[""].join("\n");
var outline_f23_36_24138=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPORTANCE OF MULTIDISCIPLINARY CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MAMMOGRAMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      BI-RADS diagnostic categories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Mammographic features of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Soft tissue mass/architectural distortion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clustered microcalcifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Assessing the extent of disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Significance of intramammary lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ULTRASONOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H667081\">",
"      Breast ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454176705\">",
"      Axillary ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BREAST MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Assessment of ipsilateral disease with breast MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Assessment of contralateral disease with breast MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365150103\">",
"      - High risk women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H365150280\">",
"      - Issues related to breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H365150166\">",
"      Effect of tumor histology on MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Effect of MRI on mastectomy rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Effect of MRI on recurrence and survival rates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Guidelines for the use of preoperative breast MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSTIC ALGORITHMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mammographic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Women with palpable masses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Younger women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Older women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H969399129\">",
"      BIOPSY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/808|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?3/17/3344\" title=\"algorithm 1\">",
"      Algorithm abnormal mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?31/37/32337\" title=\"algorithm 2\">",
"      Algorithm breast mass under 30Y",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?8/11/8383\" title=\"algorithm 3\">",
"      Bx solid lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?10/12/10435\" title=\"algorithm 4\">",
"      Algorithm breast mass over 30",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/808|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/35/36400\" title=\"diagnostic image 1\">",
"      Spot magnification MLO view",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/59/36799\" title=\"diagnostic image 2\">",
"      Spic mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/40/36495\" title=\"diagnostic image 3A\">",
"      Mass and comedo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?3/36/3663\" title=\"diagnostic image 3B\">",
"      Branching cals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/33/36368\" title=\"diagnostic image 4\">",
"      Mammo benign calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/6/42094\" title=\"diagnostic image 5\">",
"      Round cals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/808|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/0/12292\" title=\"picture 1\">",
"      Comedo ductal carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/19/39227\" title=\"table 1\">",
"      BIRADS mammography categories",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43352?source=related_link\">",
"      Axillary node metastases with occult primary breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=related_link\">",
"      Breast cysts: Clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/29/39386?source=related_link\">",
"      Breast reconstruction in women with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32249?source=related_link\">",
"      Genetic testing for hereditary breast and ovarian cancer syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1529?source=related_link\">",
"      Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/51/2872?source=related_link\">",
"      Risk prediction models for breast cancer screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_36_24139="Cryofibrinogen manifestations";
var content_f23_36_24139=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical manifestations of cryofibrinogenemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estimated prevalence, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold sensitivity",
"       </td>",
"       <td>",
"        50-80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Painful ulcerations",
"       </td>",
"       <td>",
"        45-50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Purpura",
"       </td>",
"       <td>",
"        25-30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Livedo",
"       </td>",
"       <td>",
"        25-30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urticaria",
"       </td>",
"       <td>",
"        5-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Raynaud's",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental swelling",
"       </td>",
"       <td>",
"        5-15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lower extremity nodules",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Venous thrombosis",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arterial thrombosis",
"       </td>",
"       <td>",
"        3-5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Arthralgia",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24139=[""].join("\n");
var outline_f23_36_24139=null;
var title_f23_36_24140="Defibrillation waveforms in ICDs";
var content_f23_36_24140=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51842&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Defibrillation waveforms in implantable cardioverter-defibrillators",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 181px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A shows the monophasic, exponentially decaying pulse was the waveform used in the first generation of ICDs. Figure B shows the biphasic waveform which is generated with a single capacitor by switching the output polarity during discharge. Each division is two milliseconds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24140=[""].join("\n");
var outline_f23_36_24140=null;
var title_f23_36_24141="Organisms that cause eumycetoma";
var content_f23_36_24141=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Eumycetoma etiological agents according to their frequency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Black grains eumycetomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Most frequent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Madurella mycetomatis",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Madurella grisea",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Leptosphaeria senegalensis",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Less frequent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Pyrenochaeta romeroi",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Rare",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Cladophialophora bantiana",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Corynespora cassicola",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Curvularia lunata",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Exophiala jeanselmei",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Leptosphaeria tompkinsii",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Madurella fahalii&nbsp;",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Pyrenochaeta mackinnonii",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Phialophora verrucosa",
"            </em>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            White to yellow grains eumycetomas",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Most frequent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Pseudoallescheria boydii/Scedosporium apiospermum",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Less frequent",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Acremonium falciforme",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Fusarium solani",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Rare",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Acremonium kiliense",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Acremonium recifei",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Arthrographis kalrae",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Aspergillus flavus",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Aspergillus fumigatus",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Aspergillus nidulans",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Cylindrocarpon cyanescens",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Cylindrocarpon destructans",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Cylindrocarpon lichenicola",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Neotestudina rosatii",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Paecilomyces&nbsp;lilacinus",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Phaeoacremonium&nbsp;krajdenii",
"            </em>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             <em>",
"              Phaeoacremonium&nbsp;parasiticum",
"             </em>",
"            </em>",
"            &nbsp;&nbsp;",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            <em>",
"             Polycytella hominis",
"            </em>",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24141=[""].join("\n");
var outline_f23_36_24141=null;
var title_f23_36_24142="Prevalence on PPV and NPV";
var content_f23_36_24142=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of disease prevalence on predictive values",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Consider a population of 2000 people and a diagnostic test that is 90 percent sensitive and specific. The positive and negative predictive values of the test vary when the prevalence of the disease is varied. Left panel: If the prevalence of the disease is high at 50 percent, the positive and negative predictive values will be similar to the sensitivity and specificity (90 percent, respectively). Right panel: In contrast, if the prevalence of the disease is only 10 percent, the positive predictive value decreases (50 percent), and the negative predictive value increases (99 percent).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24142=[""].join("\n");
var outline_f23_36_24142=null;
var title_f23_36_24143="Anatomic location of sinuses";
var content_f23_36_24143=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anatomy of the sinuses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing showing location of the frontal, ethmoid, and maxillary sinuses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_36_24143=[""].join("\n");
var outline_f23_36_24143=null;
